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3Overview
This thesis focuses on research with people with dementia (PWD).
Part 1 is a literature review exploring factors identified or endorsed by PWD and
their carers as influencing whether or not the person with dementia would participate
in research. A total of 16 papers were included. The quality of papers was variable,
and limitations frequent. The most prominent motivators identified for research
participation were direct health benefit and altruism. The most prominent barriers
were concerns about risks and side effects of drugs and procedures, and the
practical burden of participation. The discussion highlights key considerations for
future recruitment.
Part 2 is an empirical study examining the performance of 34 PWD on an
experience-sampling measure of mindful attention. The study aimed to develop the
evidence base for future mindfulness-based interventions (MBIs) for depression in
dementia. No significant results were found for the main hypotheses, that people
with dementia would perform significantly more poorly than a comparison group of
older adults without dementia on the measure of mindful attention, and that
performance on this measure would positively correlate with measures of executive
function and overall cognition.
Possible reasons for the findings are discussed, along with limitations of the
study, and implications for future research and clinical practice. The comparison
group data is shared with Habib (2016). The study is a substudy of an ongoing PhD
project by Joshua Stott.
Part 3 is a critical appraisal of the research process. It reflects on particular
challenges that arose in the recruitment, consent and data collection processes with
the PWD sample, outlining how these were dealt with during the study, and making
recommendations for future research.
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9Part 1: Literature review
What factors do people with dementia and their carers see as influencing
whether or not they choose to participate in research?
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Abstract
Aims
This review explored motivators and barriers to participation in dementia
research, where these had been endorsed or volunteered by people with dementia
and/or their carers.
Method
PsycInfo and Medline databases, and the Alzheimer’s Society online library
catalogue, were searched for papers published up to October 2015. Further papers
were identified through hand and online search and expert recommendation. The
quality of studies was assessed using the QualSyst tool (Kmet, Lee, & Cook, 2004)
and overall ratings assigned as per NICE recommendations (NICE, 2014).
Results
Sixteen papers were identified as meeting eligibility criteria, comprising a range
of methodologies. Quality was variable and methodological limitations common.
Data from carers were more common than from people with dementia. Narrative
synthesis revealed the most common motivators were direct benefit to the person
with dementia, and altruism. The most common barriers were concern about risks of
drugs and procedures, and practical burden. Additional factors were identified
specific to brain donation research and participation by minority ethnic populations.
Findings were tentative, and more detailed analysis difficult, due to limitations in the
identified literature.
Conclusion
The views of people with dementia and their carers on motivators and barriers
to research were generally consistent with the wider literature. Further high quality
research is needed to develop our understanding of these factors to aid the
recruitment process for dementia research studies.
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Introduction
Increasing acknowledgement of the economic, social and psychological costs
of dementia in recent years has led to a growing international emphasis on dementia
research. UK government policy (Department of Health, 2015) highlights the
importance of research infrastructure, activity and participation. Research priorities
reflect the biopsychosocial nature of dementia by addressing hopes for prevention,
identification and cure, while also aiming to help people affected by dementia – both
those diagnosed, and those supporting them – live well with the condition
(Alzheimer’s Society, 2014).
The feasibility and success of research activity depends on the recruitment of
suitable participants. There are now several large-scale projects internationally to
support this, including the Join Dementia Research hub in the UK
(https://www.joindementiaresearch.nihr.ac.uk) and the Recruiting Older Adults into
Research (ROAR) project in the US (Global Action Against Dementia, 2015). The
Prime Minister’s ‘Challenge on Dementia’ (2015) aspired to research involvement by
10% of people with dementia by 2020. A systematic review and meta-analysis
estimated that this could be realistic for pharmacological trials, if everyone
diagnosed with Alzheimer’s were invited to join a research register (Cooper, Ketley,
& Livingston, 2014), and noted the potential for recruitment to non-pharmacological
trials to be even higher (Cohen-Mansfield, 2002, cited in Cooper, Ketley &
Livingston, 2014).
Yet the challenges involved in the recruitment stage of dementia research alone
are well established. These include the difficulty in obtaining representative cohorts
of patients from primary care and the lack of awareness of research opportunities for
potential participants (Alzheimer’s Disease International, 2014), negotiating issues
of capacity and consent (Howe, 2012) and the often essential requirement to recruit
a study partner in addition to the person with dementia (hereafter abbreviated as
PWD) (Grill & Karlawish, 2010). Physical comorbidities may mean participants, even
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if willing, require additional practical support to participate (such as home visits)
(Jefferson et al., 2011), and there may be socio-cultural issues around research
within minority ethnic contexts which indicate a need for substantial work building
trust and communication if the research is to gain a foothold with underrepresented
groups (Olin, Dagerman, Fox, Bowers, & Schneider, 2002; Rabinowitz & Gallagher-
Thompson, 2010; Valle, 2005).
Researchers have extrapolated experiences from specific research projects in
order to make suggestions for improvements to future studies (Cohen-Mansfield,
2003; Watson, Ryan, Silverberg, Cahan, & Bernard, 2014). Such recommendations
tend (understandably) to be problem-focused, and to foreground the barriers to
participation in those who decline, or are unable to engage in the research process,
rather than factors motivating those who do take part. However some have
highlighted the need to develop our understanding of why a patient might choose to
participate in a study – as well as why they might decline (Vellas et al., 2012).
At the time of writing, there has not been a systematically based review of the
literature which explores both motivators and barriers to research participation from
the perspective of people with dementia. It may be assumed that the factors such a
review would identify would be similar to those noted previously by researchers, but
that assumption needs to be tested.
If such a review can provide a clearer understanding of both the pushes and
pulls of dementia research participation (and non-participation) for those directly
affected by the condition, this could aid researchers in designing more effective,
efficient recruitment strategies for their studies.
It would also reflect the growing emphasis on involving people with dementia in
all stages of research (Alzheimer's Society, 2016), and be congruent with a position
of respect for the personhood of people with dementia (Kitwood & Bredin, 1992) in
the research process more generally (Cowdell, 2006), by privileging evidence which
includes their voices.
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The current review addresses this gap, and acknowledges the often essential
role of carers in supporting the research involvement of people with dementia, by
asking the following questions:
1) What factors have people with dementia identified or endorsed as motivators
or barriers to their participation in research?
2) What factors have carers for people with dementia identified or endorsed as
motivators or barriers to the involvement of the people they care for in research?
Method
Inclusion/exclusion criteria
An initial scoping search indicated there was not a substantial existing literature
on these questions. Therefore inclusion criteria were broad.
Inclusion criteria:
a) the article contained empirical material on motivators/barriers to people with
dementia participating in research, directly provided by people with dementia and/or
their carers
b) the relevant full text article was published in a peer-reviewed journal,
accessible, and written in English
Exclusion criteria:
a) the article focused only on issues of capacity/consent/proxy decision making
as barriers or motivators to participation in research by people with dementia (since
there are recent reviews of this general area, including the systematic review by
Lord, Livingston, and Cooper (2015)
b) the article focused only on carers’ own participation in research, rather than
carers’ views on the involvement in research of the people with dementia for whom
they cared
Search strategy
PsycInfo and Medline databases, and the Alzheimer’s Society online library
catalogue, were searched for papers published up to 5 October 2015. The following
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search terms were derived from an initial review of criterion papers, and were used
in combination depending on the specific requirements of each search engine.
dementia OR Alzheimer*
AND
research OR experimentation OR clinical trial*
AND
client participation OR participa* OR taking part OR involvement
Further potential papers were identified by a hand search of the reference lists
of eligible papers, through recommendation by experts working in dementia
research, and via a search of the first twenty pages of Google Scholar, applying key
search terms. Grey literature was not searched. A search of reviews of recent
research published by the Alzheimer’s Society did not result in further papers for
screening.
Figure 1 summarises the search and screening process in a PRISMA flowchart
(Moher, Liberati, Tetzlaff, Altman/The PRISMA Group, 2009). After initial screening,
97 papers were read in full with 16 included in the final review.
16
Figure 1: PRISMA flowchart of search and study selection.
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Procedure
Given the low numbers of papers meeting the eligibility criteria, all which did so
were included, whether they related to completed, ongoing, or future/hypothesised
research with people with dementia, and whatever the methodology used
(qualitative, quantitative, mixed-method or descriptive/survey studies).
Summaries of each paper were created, and data tabulated under the following
headings: authors/date, country, design, sample/N, nature of research, key
objectives, outcomes, strengths, and limitations, and quality (see Table 1, p.19).
Authors of individual papers used different terms (proxy, surrogate,
carer/caregiver, study partner) to describe people with the same role. For ease of
reading, it was decided to use the term ‘carer’ as inclusive of all these titles, unless a
title had a particular significance (e.g. ‘proxy’ as a legal term in the context of proxy
decision-making).
As papers varied widely in method, content, and quality, a narrative synthesis
was carried out, with iterative clustering of key relevant findings from each paper. A
structure was then identified into which all the main themes were incorporated.
Assessing study quality
All studies included in the review were quality assessed (as recommended by
NICE, 2014) using the QualSyst (Kmet et al., 2004), a widely used tool which allows
appraisal of a range of designs.
Quantitative/survey designs were assessed using the 14-item QualSyst
quantitative checklist. Each study was rated by summing scores for each study
across the 14 checklist criteria (where 0 = no, 1 = partially met, 2 = yes, and n/a =
not relevant to this article), then dividing each score by the total possible score for
that study (based on relevant items only, i.e. total possible score = 28 – (number of
‘n/a’*2)).
Qualitative studies were evaluated using the 10-item QualSyst qualitative
checklist (Kmet et al., 2004). Under this checklist, all items must be completed for
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every study (with ‘yes’ = 2, ‘partial’ = 1, ‘no’ = 0), then totalled, and a summary score
provided (consisting of total score/20). As the mixed method study had a
predominantly qualitative focus, this was also evaluated using the qualitative
checklist.
As recommended by NICE (2014), rather than presenting raw scores, an
overall quality rating for each study was derived from the relevant appraisal checklist
criteria. This reflected the completeness of checklist criteria for each study and how
likely any missing criteria were to have biased the study’s main conclusions. The
three rating levels are:
 ‘++’ (most criteria fulfilled, study conclusions unlikely to alter where
these have not been fulfilled; described in the current review as ‘high quality’)
 ‘+’ (some criteria fulfilled, study conclusions unlikely to alter where
criteria unfulfilled/inadequately described; described in the current review as
‘medium quality’)
 ‘-‘ (few/no checklist criteria fulfilled, conclusions likely or very likely to
alter; described in the current review as ‘low quality’)
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Table 1: Summary of study findings
Authors/
date
Country Design Sample/n Nature of
research
Key objectives Key outcomes Key strengths Key limitations Quality
Avent et al.
(2013)
UK Survey People with
dementia
(PWD) (33),
carers (29).
Unspecified
future
studies.
Understand
motivation of
patients and
carers for joining
a dementia
research
register.
Helping others
and helping
oneself were the
leading
motivators.
Participants had
opportunity to
provide open
responses as
well as select
from closed set.
Included both
PWD and
carers.
High (80%)
participation
rate.
Presentation of data
means not possible
to separate/
compare PWD and
carer responses.
Only sampled
existing registrants.
Assesses
motivation to join
register – not an
actual study.
+
Black et al.
(2013)
USA Qualitative PWD (39),
carers (46).
Current drug
and non-
drug studies,
unspecified
future
studies.
Explore
decision-making
process of those
who consented
to participate in
research.
Helping the
person with
dementia was
the most
common
motivator.
Altruism/helping
others second
most common.
Included both
PWD and
carers.
Real studies.
Records
differences in
response by
study type.
Rigorous
methodology.
All bar one
respondent had
consented to a
study – those who
declined may have
held different
attitudes.
Data mainly
retrospective.
Most studies low
risk/non-
intervention.
++
Cohen-
Mansfield et
al. (2002)
Israel Survey PWD/carers
(53).
Completed
drug study.
Reasons for
refusing to join a
drug study.
Potential
harm/lack of
benefit were key
in refusal.
Included both
PWD and
carers.
No apparent
limitation on
response
options.
Presentation of data
– cannot distinguish
PWD from carer
responses.
Limited focus
(reasons for refusal
of a drug study).
Unclear
methodology.
Retrospective data.
-
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Authors/
date
Country Design Sample/n Nature of
research
Key objectives Key outcomes Key strengths Key limitations Quality
Connell et al.
(2001)
USA Qualitative Carers (50) Longitudinal
research
programme
with varied
elements.
Examine white
and African-
American carer
attitudes
towards
research
participation.
Key themes
identified:
benefits, barriers
and resources
relevant to
participation.
Rigorous
methodology.
Real (current)
research
programme.
Sampled carers
only.
All participants had
already consented
to the research
programme.
Retrospective data.
++
Dunn et al.
(2011)
USA Mixed
method
Carers (82) Hypothetical
drug and
non-drug
studies.
Explore decision
making for three
hypothetical
research
studies.
Main motivators
included
altruism and
direct benefit to
PWD. Barriers
included
inconvenience,
risk, and
patient’s lack of
interest.
Answers varied
by study type.
Explored
different study
types.
Incorporated
both open and
more structured
questioning.
Explored both
motivators/
barriers, not
biased by
existing
participation.
Sampled carers
only.
Hypothetical studies
only.
Process of content
analysis unclear.
+
Elad et al.
(2000)
Israel Survey Carers (29) Current drug
trial.
Explore factors
affecting carers'
decisions to
allow/refuse
participation by
PWD.
Key motivators:
hope for direct
benefit to PWD,
altruism,
recommendation
by physician/
family. Leading
barriers:
concerns re
drug risk/
efficacy, burden
on PWD/carer.
Real study
(current).
Sampled carers
who had either
enrolled or
declined a
study.
Sampled carers
only.
Unclear whether
questionnaire
allowed open
responses, or
extent of any limits
on possible
responses.
+
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Authors/
date
Country Design Sample/n Nature of
research
Key objectives Key outcomes Key strengths Key limitations Quality
Guerriero-
Austrom et al.
(2011)
USA Qualitative Carers (30) Ongoing
brain
donation
programme
(FTD).
Identify attitudes
about brain
donation in
carers, to aid
understanding of
variables that
may improve or
act as barriers to
participation.
Key themes:
motivations
included direct,
indirect and
altruistic benefit
for PWD and
family. Barriers
included lack of
effective
communication
with the
research team.
Real study.
Rigorous
methodology.
Included both
carers who had
consented to
and declined
studies – less
chance of
positive bias.
Sampled carers
only.
++
Hinton et al.
(2000)
USA Qualitative Carers and
PWD from
25 families
Study of
dementia
caregiving
(recruitment
stage).
Identify socio-
cultural barriers
to recruiting
PWD and their
families to a
research project.
Three key
themes:
dementia seen
as normal aging,
not warranting
clinical/research
attention; fear of
research
causing
worry; stigma of
dementia
diagnosis.
Rigorous
methodology.
Real study
(current).
Study focuses on
one minority ethnic
population which
may affect
generalisability.
++
Karlawish et
al. (2001)
USA Qualitative Carers (22) Current drug
trial.
Explore
decision-making
factors for
carers and
differences
between those
who consented/
declined
research
participation for
PWD.
Main motivators:
potential direct
benefit, trust in
institutions,
altruism,
desperation.
Main barriers:
perception of
practical
burdens,
possible harm.
Emphasis on
interdependence
of risks/benefits
for carer/PWD.
Real (current)
study.
Rigorous
methodology.
Potentially less
chance of
positive bias as
sample included
those who’d
enrolled,
declined, or
been judged
ineligible.
Sampled carers
only.
++
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Authors/
date
Country Design Sample/n Nature of
research
Key objectives Key outcomes Key strengths Key limitations Quality
Karlawish et
al. (2002)
USA Survey PWD (15),
carers (15)
Hypothetical
drug trials.
Reasons for
enrolling for
PWD and their
carers in an
early phase
clinical trial.
Main motivators:
direct health
benefit to PWD,
altruism. Main
barriers: burden
of participation.
Includes both
PWD and
carers.
Hypothetical study
only, fewer details
supplied to
participants than for
real studies.
Does not
differentiate
between PWD and
carer responses.
Does not quantify
responses.
All were existing
participants in
research studies.
+
Karlawish et
al. (2008)
USA Quantitative Carers (108) Hypothetical
future clinical
trials.
Explore how
varying four
practical
elements of a
study affects
carers’
willingness to
participate.
Highest utility
assigned to
home visits
(balancing out
disutility of high
risk). Value of
reducing travel
inconvenience
positively
correlated with
dementia
severity.
Range of
options available
to respondents
allowed deeper
exploration of
practical
barriers.
Rigorous
methodology/
statistical
analysis.
Sampled carers
only.
Hypothetical studies
only.
++
Lynöe et al.
(1998)
Sweden Survey Carers (19) Completed
study - blood
sample/
health record
check.
Reasons for
allowing PWD to
participate.
Altruistic
reasons most
frequently/
strongly
endorsed (but
only limited
range of
response
options
provided).
Real study. Sampled carers
only, all had already
participated.
Limited response
choices apparently
offered,
methodology of
questionnaire
unclear.
Retrospective data
only.
-
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Authors/
date
Country Design Sample/n Nature of
research
Key objectives Key outcomes Key strengths Key limitations Quality
Mastwyk et al.
(2002)
Australia Survey Carers (25) Completed
drug trials.
Determine why
carers seek
participation of
PWD in clinical
trials.
Dominant
factors endorsed
were direct
health benefits
to patient and
altruistic
motives.
Real
(completed)
studies.
Carers only, and
only sampling those
who had taken part
in the study.
Limited response
choices offered re
motivators only.
Questionnaire
methodology
unclear.
Retrospective data
only.
-
Mastwyk et al.
(2003)
Australia Survey Carers (44) Completed
drug trial.
Explore carer
motivations for
seeking
participation of
PWD in drug
trial.
Main motivators:
direct benefits
and altruism.
Other factors
included
recommendation
by others and
non-health
benefits.
Real
(completed)
study.
Included carers
who had not
been accepted
to the study
(screening only
group).
Carers only.
Limited response
choices offered re
motivators only.
Questionnaire
methodology
unclear.
Retrospective data
only.
+
Sugarman et
al., (2001)
USA Qualitative Carers (49) Variety of
current/
completed
drug and
non-drug
studies.
Explore how
carers make
decisions about
research for
PWD.
Drug trials: main
motivators were
direct
benefit/lack of
options/
desperation,
altruism also
prominent. Non-
drug studies:
main motivators
were altruism
and hope of
better care.
Trust in doctor/
institution
important.
Real studies
(completed and
current, range of
types).
Rigorous
methodology.
Sampled carers
only, all of whom
had already
consented to a
study.
Retrospective data
only.
++
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Authors/
date
Country Design Sample/n Nature of
research
Key objectives Key outcomes Key strengths Key limitations Quality
Williams et al.,
(2001)
USA Qualitative Family
members/
carers –
numbers
unclear.
Current
exercise
intervention
study
(recruitment
stage).
Exploration of
reasons for high
refusal rate in
Cuban American
nursing home
residents with
aim of improving
recruitment.
Main themes:
perception of
PWD’s need for
contentment and
solitude, and the
futility of
intervening.
Part of a real
study with PWD.
Study focuses on
one minority ethnic
population which
may affect
generalisability.
Unclear
methodology.
-
Note: The eligibility of some papers was based on a subsection of a wider study. For these papers, the design selected, and quality rating assigned, applies to the subsection
only.
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Results
Overview of included studies and limitations
Sixteen studies met the eligibility criteria. Ten were from the USA, one from the
UK, two from Australia, two from Israel, and one from Sweden. Seven were
assessed as high quality (six qualitative papers, and one quantitative), five as
medium quality (four surveys and one mixed-method paper), and four as low quality
(three surveys and one qualitative paper). Overall, the review comprises seven
qualitative studies, seven surveys, one mixed-method study and one quantitative
study.
Eleven papers included data from carers only, and five included data from
people with dementia and carers. Unfortunately papers did not always clearly
distinguish their responses, reducing the utility of the studies to the current review.
Studies focused on a diverse range of research types. Pharmacological studies
were most common, but papers also covered joining a research register, physical
intervention, longitudinal studies comprised of various elements, diagnostic/medical
studies and brain donation.
Across the included studies, the majority of interviewees/respondents were
white, and carers were predominantly female. Small sample sizes and limited
sample sites were standard. Studies varied in whether they assessed real or
hypothetical scenarios. Data for real studies were frequently retrospective.
Motivators
Twelve of the sixteen papers included discussion of factors motivating research
participation.
Direct benefit to the PWD
Ten studies mention direct benefit to the PWD as a leading motivator for
research participation. These comprised four high quality qualitative studies (Black,
Wechsler, & Fogarty, 2013; Connell, Shaw, Holmes, & Foster, 2001; Karlawish,
Casarett, Klocinski, & Sankar, 2001; Sugarman, Cain, Wallace, & Welsh-Bohmer,
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2001), one medium quality mixed-method paper (Dunn, Hoop, Misra, Fisher, &
Roberts, 2011), four medium quality survey studies (Avent et al., 2013; Elad et al.,
2000; Karlawish, Casarett, & James, 2002; Mastwyk, Macfarlane, LoGiudice, &
Sullivan, 2003), and one low quality survey study (Mastwyk, Ritchie, LoGiudice,
Sullivan, & Macfarlane, 2002). This hoped-for benefit was framed both generically
and specifically.
Three papers mention non-specific direct benefit to the PWD. Black et al.
(2013) interviewed 39 people with dementia and 46 carers about how they decided
whether to consent to a range of drug and non-drug studies. The leading motivator
in both groups was the desire to help the PWD, mentioned by 74% of people with
dementia (25/34) and 80% of carers (36/45). Strengths of this study include
incorporating detailed qualitative interview data from both carers and people with
dementia relating to a range of real research studies (current and future), as well as
providing descriptive data for interview themes, allowing more detailed analysis of
findings. Limitations include data being retrospective, and the fact that most
participants had already consented to research.
Direct benefit was the second most frequently mentioned motivator to enrol in
Dunn et al. (2011), being mentioned by 18% of carers (15/82, 13 of whom said they
would enrol) across study types. This paper explored motivators and barriers to
participation across three hypothetical studies (MRI/imaging, a drug trial, and a
vaccine trial). The methodology made it possible to explore responses to a range of
research scenarios, while avoiding the issue of potential bias linked to respondents
having consented to participation in a genuine study. However the fact that all
studies were hypothetical may have affected responses.
In Avent et al.’s 2013 survey of reasons for joining a dementia research
register, 27% (28/102) mentioned ‘Research might help me/patient I care for’ as a
motivator in the free text response section, with 81% (81/100) endorsing this as
important in the closed response section. It was selected as ‘most important’ by 29%
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(26/91), making it the second most valued motivator overall. The survey did not
explore views about a specific study, but asked people with dementia and carers
about motivations for joining a research register. As all respondents were already
registered, data may have been positively biased. The sample included people with
dementia, carers (who had registered in their role as proxy for a PWD), and carers
who had registered in their own right. Views of groups are not clearly distinguished
in the results, reducing the utility of the data to the current review.
Specific health benefit
Seven of the ten studies gave specifics about the health benefit carers hoped
people with dementia would experience via research involvement.
Connell et al. (2001) summarised interview data from 50 carers under three key
themes: one of these was ‘Benefits’ (of participation), with the subtheme of ‘Access
to Diagnosis, Care, and Treatment’ including the hope for slowing of disease
progression. The study benefited from a rigorous methodology, exploring both
motivators and barriers to participating in a real research programme, and having an
additional focus on the experience of African American research participants.
However only carers were interviewed, all data is retrospective, and the
interviewees were already involved with an existing programme.
Karlawish et al. (2001) interviewed 22 carers who had been prospective study
partners in a drug study (nine enrolled, eight declined, and five were found
ineligible), exploring reasons for/against enrolment. Potential for direct medical
benefit to the PWD was the leading motivator, volunteered by 100% of carers who
enrolled in the study (9/9). Though data were retrospective, and only carers were
interviewed, strengths included the study being a genuine one, and views being
sampled from those who had declined/been found ineligible as well as those who
participated.
Sugarman et al. (2001) interviewed 49 carers of people who had supported
PWD participation in a range of study types (32 in a genetic study, 20 in drug trials,
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10 in an imaging study, two in a cognitive intervention, two in an epidemiological
study, with some enrolled in more than one). For those involved in drug studies,
researchers found ‘hope for direct benefit’ as one of four key themes in participant
interviews, specifying that this incorporated slowed progression, increased life span,
and improved quality of life. Strengths of the study included the research being
genuine, and the methodology allowing for a broad exploration of both motivators
and barriers to participation across different study types. Limitations included only
carers who had already consented to participation being interviewed, and data being
retrospective.
Elad et al. (2000) sampled 29 carers, 10 of whom had declined and 19 who had
enrolled in a drug trial. Sixty-three per cent (12/19) of those who enrolled endorsed
‘hope for improvement in condition’ as the leading reason for their participation, with
47% (9/19) mentioning hope for ‘stabilisation/maintenance’ in the dementia.
Strengths of the study include that it involved both those who joined the study and
those who declined it, and that the study was real. Limitations included only carers
being sampled, data being retrospective, and the methodology of the survey
component being unclear (e.g. whether answers were given in the context of open
questioning or limited response options).
Karlawish et al. (2002) described potential benefit to the patient’s health or
wellbeing as ‘typically featuring’ in reasons to enrol in a hypothetical drug trial by
47% of PWD (7/15) and 40% of carers (6/15). The study benefits from incorporating
data from both people with dementia and carers, and exploring both motivations and
barriers to participation. However the trial was hypothetical, the study did not
distinguish patient and carer responses, and all respondents were already involved
in research.
Mastywk et al. (2003) surveyed 44 carers of people with dementia who had
completed a drug trial. Ninety-six per cent (26/27 who responded) of carers of the 29
people in the treatment group endorsed ‘Help relative feel better’ as the leading
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reason for participation, with 73% (19/26 who responded) endorsing ‘Help relative
live longer’ as the second most important reason. These were also the most
popularly endorsed motivators to participation among the 15 carers who were
screened only, with 93% (14/15) agreeing with both statements. The paper’s
strengths included being based on a real study and including data both from those
judged ineligible for a study and those who had participated. It was limited in offering
a restricted range of options for response (focused on motivating factors only) and
data being retrospective.
Mastwyk et al. (2002) received responses sufficient for analysis from 25/ 31
carers who had supported the people they cared for to participate in a drug trial
(though not all carers appear to have responded to every item). All 21 people
(100%) who responded endorsed the item ‘Help relative feel better’, identifying it as
the leading reason for their participation, with 81% (17/21) endorsing ‘Help relative
live longer’, making it the joint third most popular reason. The survey shared the
strength of Mastwyk et al. (2003) in being based on real research, but also shared
its limitations. Unlike Mastwyk et al. (2003) it sampled only those included in the
drug trial.
Diagnosis
Specific hopes that research participation would help with diagnosis were found
in two studies.
Black et al. (2013) found that that ‘desire to get a diagnosis’ was one of the
most common factors underlying the leading motivator for participation, to help the
PWD, while Connell et al. (2001) identified the hope for definitive diagnosis under
the subtheme of ‘Access to diagnosis, care and treatment’.
Most papers which did not include diagnosis as a motivating factor focused on
drug trials. This may be because having an existing diagnosis of dementia would be
a prerequisite for entering the study, and therefore the hope of diagnosis could not
be a motivator to do so.
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Monitoring/treatment
Six of the ten studies mentioning direct benefit specified monitoring and/or
treatment as a motivator.
Black et al. (2013) noted that 6% of interviewees with dementia (2/34) and 11%
of carers (5/45) mentioned ‘being informed of new treatments or other studies’ as a
motivator for participation.
Connell et al. (2001) identified the hope of receiving better care, and access to
medications and potential cures, as part of the subtheme of ‘Access to Diagnosis,
Care, and Treatment’ (under ‘Benefits’, one of three headline themes).
Sugarman et al. (2001) records hopes from two interviewees that participation
could gain their relative experimental or ‘leading edge’ treatment.
Seventy-five per cent (75/100) of respondents in the forced choice response
section of Avent et al.’s 2013 survey endorsed as ‘important’ the statement that
research involvement might help with monitoring a person’s dementia. None
mentioned it in the free response section, and only 10% (9/91) saw it as the most
important motivator to their registration with the research database. Forty-eight per
cent of respondents (48/100) agreed that the possibility of accessing treatment not
available on the NHS was ‘important’ in the forced choice section (though no-one
identified it in free response), and only 8% (7/91) agreed it was the most important
motivator.
In Mastwyk et al. (2003), 93% (25/27 respondents of the treatment group of 29)
rated the hope that the drug would cure their relative as extremely/moderately
important, with 85% (11/13) of respondents from the screening only group (N = 15)
agreeing. Receiving ‘Free specialist care and attention’ was rated as
extremely/moderately important by 17% (4/23) of the 29 respondents in the
treatment group, with 39% (5/13) of the screening only group agreeing.
Ninety per cent of respondents (18/20, of 25 sampled) to the survey by
Mastwyk et al. (2002) endorsed ‘The hope the drug would cure’ as extremely or
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moderately important, making this a key motivator for participation, with ‘Free
specialist care or tablets’ seen as extremely/moderately important by 41% (7/17)
respondents.
Social/emotional benefit
This was included in only two studies.
Black et al. (2013) notes that people with dementia were less motivated than
carers by the hope of emotional support, though how many times this was
expressed is not stated.
The carer’s hope for social benefit for the PWD was noted in Dunn et al. (2011).
Two of 82 carer interviewees who consented to hypothetical MRI/behavioural or
drug studies gave ‘socialisation for patient’ as a motivator to enrolment (making it
one of least frequent responses).
Financial benefit
Only two studies directly mention financial benefit, though one may make
implicit reference to this.
Black et al. (2013) notes ‘financial reasons’ were mentioned by 6% (20/34) of
people with dementia and 4% (2/45) of carers as a motivator for research
participation, though this was among the lowest priority reasons volunteered.
Though none of the respondents in Avent et al. (2013) volunteered payment as
a motivator in the free response section of the survey, when offered it as an option
in the forced choice section, 8% (8/100) agreed it was ‘important’. Only 1% (1/91)
agreed it was the most important factor in their participation in a research register, a
rate the authors note is less than chance. It is not possible to tell from the study
whether respondents were carers or people with dementia, and the question did not
relate to a real study, or specify an amount.
While carer interviewees in Sugarman et al. (2001) did not report financial
compensation as a likely motivator, their responses were given in the context of
receiving $25 for each telephone interview they completed.
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Summary
Direct benefit for the PWD was a leading motivator for research participation in
the majority of papers. These benefits were most commonly identified as hoped-for
positive medical impact on the PWD’s condition, or better condition
management/future treatment. Non-medical (social or financial) direct benefits were
infrequently mentioned.
Benefit to carers
Nine of the 12 papers discussing motivators mention benefit to carers: three
high quality qualitative studies (Black et al., 2013; Guerriero-Austrom et al., 2011,
Sugarman et al., 2001), one high quality quantitative survey (Karlawish et al., 2001),
one medium quality quantitative study (Dunn et al., 2011), three medium quality
surveys (Avent et al., 2013, Mastwyk et al., 2003, Elad et al., 2000) and one low
quality survey (Mastwyk et al., 2002). Such benefits were framed both generally and
more specifically.
In Black et al. (2013), 40% of carers (18/45) and 18% of people with dementia
(6/34) mentioned being motivated by potential benefit to the carer, or family. It is not
possible to tell from the data as presented whether ‘carer’ and ‘family’ are intended
to represent different concepts.
As also noted under ‘Direct benefit to the PWD’ (p.26), Avent et al. (2013) noted
‘Research might help me [i.e. the carer]/patient I care for’ as the second most
important motivator in joining a research register. As the study did not distinguish
responses of carers and people with dementia, it is unclear how often this response
related to carer benefit rather than benefit to the PWD.
Diagnosis
Guerriero-Austrom et al. (2011) explored barriers and motivators to participation
in a brain donation programme in focus group interviews with 30 carers of people
with frontotemporal dementia (FTD). Getting a definitive post-mortem diagnosis was
the leading motivating factor to participation identified by carers. This can be
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understood in the context of the higher familial risk of this form of dementia. Though
the study was limited by sampling carers only, and data being retrospective, it may
have been at less risk of positive bias since it included both people who had
declined and those who had consented to involvement in a research programme,
was based on real research, and had a rigorous methodology.
Emotional support
As noted above under ‘Social/emotional benefit’ for people with dementia
(p.31), carers in Black et al. (2013) were more motivated than people with dementia
by the hope of receiving emotional support, though how many times this was
expressed is not stated.
In Mastwyk et al.’s 2002 survey, 58% (11/19) of carers endorsed ‘Having
someone to talk to’ as ‘extremely’ or ‘moderately’ important. In Mastwyk et al.
(2003), 63% (15/23) in the treatment group endorsed this item, vs 36% (4/11) in the
screening-only group.
Desperation, hope, and agency
Karlawish et al. (2001) found that desperation was the fourth most common
motivator to enrolment among those who consented (cited by 44%, 4/9). The study
was unusual in sampling carers who had either consented to, declined, or been
judged ineligible for a current drugs trial, and was able to explore differences and
similarities between these groups.
The sense of there being nothing to lose emerged as a theme for several
interviewees in Dunn et al. (2011), though the number mentioning this is not
recorded. One interviewee specifically mentioned ‘desperation’ as a motivator for
participation. Two interviewees mentioned that a ‘feeling of taking action’ would
motivate participation in the hypothetical studies discussed.
In Sugarman et al. (2001), themes of nothing else being available, and
desperation, represented two of the four areas seen as key in the complex process
of deciding to participate in research. These themes were more frequently
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mentioned by carers partnering people with dementia involved in drug trials, and
where the person’s dementia was more severe.
Elad et al. (2001) found that maintenance of hope was the third most frequently
mentioned motivator, given by 21% (4 of 19 respondents) who had joined a drug
study).
Summary
Two-thirds of studies mention benefits to carers as motivating research
participation, though not generally as a leading factor. The exception was the brain
donation study. Such benefit comprised diverse elements; one of the most
frequently cited was desperation/need to maintain hope.
Altruistic motivators
Helping others/advancing science.
These general altruistic motivators were mentioned in all 12 papers discussing
motivators, and frequently appeared in the top three reasons for participation
mentioned by both people with dementia and carers.
In Black et al. (2013), 62% (21/34) of people with dementia and 53% of carers
(24/45) mentioned the wish to ‘help people in the future’ – making it the second most
popular motivator.
Connell et al. (2001) found ‘Helping others’ to be one of three key motivational
subthemes identified from interview data, under a major theme of ‘Benefits’ to
participating in research.
A study of barriers/motivators to participating in a brain donation programme for
people with FTD (Guerriero-Austrom et al., 2011) describe ‘advancing scientific
knowledge’ as one of the three primary motivators to participation.
Karlawish et al. (2001) found the desire to benefit other patients with
Alzheimer’s disease was mentioned by 56% (5/9) of carers who agreed to enrolment
in a drug study, making it one of the top four motivating factors, though most of
these carers said this reason was more important to the PWD than it was to them.
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Altruism was identified as a primary motivator for participation in Sugarman et
al.’s 2001 interviews when the trials were non-pharmacological; for drug studies,
altruism was a secondary motivator (after direct benefit to the PWD).
Thirty-five per cent (29/82) of interviewees in Dunn et al. (2011) mentioned
‘altruism’ as their main motivation for consenting to drug or non-drug studies,
making this the leading motivator overall.
Forty-seven per cent (48/102) of respondents to the free response section of
Avent et al.’s 2013 survey stated ‘research might help others’ had been the most
important motivator for joining the research register. Eighty-six per cent (86/100) of
respondents in the forced choice section agreed it was important, with 44% (40/91)
agreeing it was the most important reason for registration. This made it the leading
motivator for respondents.
Elad et al. (2000) found that 11% (2/19) of those who enrolled in a drug study
mentioned contributing to science as a motivator, though this trailed the primary
motivator of direct benefit.
Karlawish et al. (2002) state that reasons for enrolling in (hypothetical) drug
trials ‘typically featured’ helping others/one’s family/contributing to scientific
knowledge.
In Mastwyk et al. (2003), altruistic motives were among the highest rated, with
96% of carer respondents (23/24) from the treatment group endorsing ‘Improve the
health of others’ as extremely/moderately important, with 85% (12/14) of the
screening-only group agreeing. Ninety-two per cent (23/26) in the treatment group
also endorsed ‘Contribute to science’, with 80% (12/15) of the screening-only group
agreeing.
In a low quality survey study (Lynöe, Sandlund, & Jacobsson, 1998), 71%
(15/21) ranked ‘the benefit of future patients’ as of first or second importance in their
decision to participate, while 43% (9/21) ascribed the same importance to ‘the
benefit of science’. Strengths of this paper included being based on a real study
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(blood test and health records check), but it had extensive limitations – survey
response options were restricted to indirect motivating factors, methodology was
unclear, and only carers who had consented to the study were sampled.
Ninety-five per cent (20/21) of respondents in Mastwyk et al. (2002) endorsed
‘Contribute to medical science’ as an extremely/moderately important motivation,
while 94% (17/18) similarly endorsed ‘Improve the health of others’.
Altruistic motivations were framed as matters of morality/obligation in two
studies. In Lynöe et al. (1998), 2/21 carers endorsed the item, ‘To participate is a
way for the Alzheimer patient to be useful’. Carer interviewees in Sugarman et al.
(2001) commented (for non-pharmacological studies) on the motivation of being a
good citizen and the obligation to help others.
Altruism/benefit to wider family
The altruistic wish to benefit family members was mentioned in six papers; four
high quality qualitative studies (Black et al., 2013; Connell et al., 2001; Sugarman et
al., 2001; Guerriero-Austrom et al., 2011), one medium quality mixed-method study
(Dunn et al., 2011), and one medium quality survey study (Karlawish et al., 2002).
In Black et al. (2013), 18% of people with dementia (6/34) and 40% of carers
(18/45) mentioned being motivated by potential benefit to the family (or carer), as
opposed to direct benefit to the PWD. Helping one’s family was one of the ‘typically
featuring’ motivators for consenting to a (hypothetical) drug trial in Karlawish et al.
(2002), and was stated as a reason for joining a (non-drug) study by three carer
interviewees in Dunn et al. (2011).
Helping family formed part of the subtheme of ‘helping others’ identified under
the headline themes of ‘Benefits’ to research participation in Connell et al. (2001),
and interviewees in Sugarman et al. (2001) volunteered helping
children/grandchildren as one aspect of the altruistic motivations which were the
main reason for consenting to non-drug studies, and also represented a secondary
reason for consenting to other study types.
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The wish to benefit family members may be a particular driver when there is a
potential for inherited risk of a particular dementia. Providing risk information for
family members was one of three primary motivators (along with getting a definitive
diagnosis, and advancing knowledge) mentioned by carers in Guerriero-Austrom et
al. (2011).
Summary
Altruistic factors were always among the leading motivators for research
participation, and were mentioned across all 12 papers. Half of these specifically
mentioned future benefit to the PWD/carer’s family.
Relationship with clinician/institution
The relationship with the sponsoring clinician or institution was mentioned in
eight studies: three high quality qualitative studies (Black et al., 2013; Karlawish et
al., 2001; Sugarman et al., 2001), one medium quality mixed-method study (Dunn et
al., 2011), three medium quality survey studies (Elad et al, 2000; Avent et al, 2013;
Mastwyk et al., 2003, and one low quality survey study (Mastwyk et al., 2002).
In Black et al. (2013), 35% (12/34) of people with dementia and 16% (7/45) of
carers expressed trust in the clinician or the university hosting the study as a
motivator. This was the third most popular motivator mentioned by people with
dementia, and the fourth most popular with carers.
‘Trust’ was one of the top four reasons for enrolment in a drug trial, mentioned
by 56% of carers (5/9) who consented to the study in Karlawish et al. (2001). The
researchers identified three separate ‘domains of trust’ for respondents – in the
principal investigator/clinic, the hosting university, and the sponsoring
pharmaceutical company, and understood these as helping participants overcome
uncertainty about their scientific understanding of the project, and manage their
feelings of desperation.
Sugarman et al. (2001) identified ‘trust in physician or institution’ as a theme in
some responses (for those who had consented to non-drug studies), with
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interviewees explaining that this trust made it easier to override the need to fully
understand the research, as if the doctor had asked for their involvement, ‘it must be
worthwhile’.
Institutional trust (in terms of safeguards/monitoring) was mentioned by 61%
(5/82) interviewees in Dunn et al. (2011). This made it the third highest motivator
recorded, through it trailed the top two motivators of altruism and potential direct
benefit to the patient.
Trust in/recommendation from a professional was also expressed as a
motivator in Elad et al. (2000) (by 11%/2/19 respondents who had enrolled in a drug
study).
In Mastwyk et al. (2003), ‘Doctor recommended’ was endorsed as
extremely/moderately important by endorsed by 18% (3/17) of the treatment group,
and 54% (6/11) of the screening-only group; the item was similarly endorsed by 56%
(9/16) of those who responded in Mastwyk et al. (2003).
Summary
Trust in a clinician or institution connected with the research was consistently
mentioned as a high-ranking motivator in studies, though never the leading one.
Barriers
Eleven of the 16 papers included some discussion of barriers to participation.
Two of these focused on specific cultural groups (Hinton, Guo, Hillygus, & Levkoff,
2000; Williams, Tappen, Buscemi, Rivera, & Lezcano, 2001) and are incorporated in
a separate section below, along with Connell et al.’s African American interviewee
data, so as not to dilute the specificity and thematic importance of these findings.
Lack of direct benefit
Concern about lack of direct benefit to the PWD was mentioned as a barrier in
four studies – one high quality qualitative study (Connell et al., 2001), one medium
quality mixed-method study (Dunn et al., 2011), one medium quality survey study
(Elad et al., 2000), and a low quality survey study (Cohen-Mansfield, 2002). All
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sampled participants where joining a drug trial (real or hypothetical) had been
suggested.
The idea of participation offering ‘no direct benefit’ to the PWD was the primary
barrier raised by carers in Connell et al. (2001), with one interviewee expressing
concern that ‘it would all be for nothing’ if the person they cared for was put in the
placebo condition. It should be noted that all carer interviewees in Connell were
already enrolled in research, so it is not unclear if the potential lack of direct benefit
had actually acted as a barrier to participation.
An interviewee in the study by Dunn et al. (2011) stated that she felt her partner
needed ‘real medicine’ not a placebo, and 4% (3/82) of interviewees (all from the
group who had declined a hypothetical vaccine study) gave ‘possible lack of benefit’
as a reason.
Fifty per cent (5/10) carer respondents in Elad et al. (2001) who had declined
consent to a drug trial mentioned concern that the drug involved would not work.
Six per cent (3/53) of respondents in Cohen-Mansfield et al. (2002) mentioned
lack of direct benefit as a reason for declining a drug trial. The study sampled both
carers and people with dementia who had declined to participate in the trial, asking
for their reasons. This open questioning on reasons for declining the study
facilitated a wide range of different responses, and both carers and people with
dementia were questioned. However the methodology is unclear, and responses
from people with dementia and carers are not distinguished.
Summary
Several studies note the possibility of lack of direct benefit, in the form of
ineffective or placebo medications being provided in a drug trial, as a barrier to
participation. This was rarely a primary concern.
Fear of negative impact
Six papers of the 16 including coverage of barriers noted fear of negative
impact on the PWD in various forms, including two high quality qualitative studies
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(Connell et al., 2001; Karlawish et al., 2001), one medium quality mixed-method
study (Dunn et al., 2011), two medium quality survey studies (Elad et al., 2001;
Karlawish et al., 2002), and one low quality survey study (Cohen-Mansfield et al.,
2002).
Risks of drugs and procedures
Five papers discussed concern about the risks of the drugs or procedure to the
PWD as a barrier to research participation.
Concern about the potential negative impact of research procedures and tests
was identified in Connell et al. (2001) as one of six subthemes under a headline
theme of ‘Barriers’.
The potential side effects of the study drug were one of the three most common
barriers mentioned by carers in Karlawish et al. (2001), mentioned by 38% (3/8) who
declined to enrol in the study.
Worry about potential risks from drugs were mentioned by 27% (22/82) of
interviewees in Dunn et al. (2011), and was the second most common barrier
identified. Nine per cent (7/82) specifically mentioned concern about the impact of
procedures on the PWD.
In Elad et al. (2001), 60% (6/10) of carers who refused to participate in a drug
trial gave concern about side effects as a reason, and this was the most frequently
expressed barrier.
In Karlawish et al. (2002) 20% of carers (3/15) and 13% of people with
dementia (2/15) mentioned potential medication risks, physical or mental discomfort
as a barrier to enrolment in a hypothetical early phase clinical trial, though the
author does not include these in the group of ‘typically featuring’ reasons.
Concerns re participants’ health
Three papers found other concerns about how the PWD’s health would be
affected by participation, or affect their ability to participate.
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In Karlawish et al. (2001), the wish not to alter the patient’s vitamin dosage for a
specific trial was mentioned by 38% (3/8) who had declined a drug trial.
Nine per cent of interviewees (7/82) in Dunn et al. (2011) expressed concerns
about other medical conditions, and 7% (6/82) referenced the persons’ current
severity of dementia, as barriers to participation – interviewee quotes suggest that
this was related to the perception that no direct benefit was possible and thus risks
would outweigh benefits, or because the PWD was seen as not being fit to
participate.
In Cohen-Mansfield et al. (2002), concern about threat to the patient’s stability
was the most frequently given reason for refusing participation in a drug trial, being
mentioned by 66% of interviewees (35/53). Concern about increased agitation was
the second most frequently mentioned (by 45%, 24/53). As previously noted, the
utility of the data is restricted by the limited detail provided and the lack of distinction
between carer and PWD responses. In the same study, 38% (20/53) gave the
reason that the person’s existing medication was working. The PWD currently being
‘psychotic/delusional’ (mentioned by 17%, 9/53) or psychologically unable in some
other way to take part (mentioned by 8%, 4/53) were among less frequent reasons
for declining the study.
Summary
Concerns about risks and side effects of a drug as a barrier to participation, as
well as the impact of procedures, were highly ranked concerns in four studies. The
same number mentioned more general concerns about the PWD’s health and
wellbeing as a barrier to participation, though generally ranking this less highly.
Practical burden of participation
The burden on participants of involvement in dementia research appeared as a
barrier in six papers. These were made up of two high quality qualitative studies
(Karlawish et al., 2001; Connell et al., 2001), one high quality quantitative study
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(Karlawish et al., 2008), one medium quality mixed-method study (Dunn et al., 2011)
and two medium quality survey studies (Elad et al., 2001; Karlawish et al., 2002).
In Karlawish et al. (2001), general hassles and burden, including travel, was the
main reason given by carers who declined enrolment in a drug study (mentioned by
50%, 4/8). The study suggested that this concern may have interacted with other
care-related factors, since those citing it as a barrier to participation did not have
longer journeys than those who did not mention travel as an issue. One carer
specified concern that participation could increase her mother’s stress levels,
making it more difficult for her and her father to maintain their caring roles.
‘Insufficient time and resources’ was identified as one of six subthemes under a
headline theme of ‘Barriers’ in Connell et al. (2001).
Karlawish et al. (2008), explored how much utility/disutility carers assigned to
different practical elements of research participation. The study concluded that
clinical trials that reduce travel inconvenience (for example by arranging transport)
may offset the barriers of factors such as the risk of a clinical intervention, and
thereby increase participation. Although the study sampled carers only, and related
to hypothetical research, its large sample size (108 carers) allowed for detailed
parametric analysis of the data.
‘Inconvenience’ was the most frequently mentioned barrier to participation in
Dunn et al. (2011), given by 38% (31/82) interviewees across hypothetical study
types (MRI/imaging, drug trial, vaccine trial).
Thirty per cent (3/10) of carers who refused consent to a drug study (Elad et al.,
2001) gave physical burden on the patient as a reason, and 20% (2/10) mentioned
physical burden on the carer.
Burden of participation (such as overnight stay in a research unit, or frequent
study visits) was noted as a typical reason volunteered by carers and people with
dementia for refusing to participate in a hypothetical drug trial in Karlawish et al.
(2002).
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Summary
Inconvenience and practical burden were frequently identified as barriers to
research participation, and sometimes as the primary barrier.
Cultural factors
Specific intra-cultural barriers to participation were a focus in three studies: two
high quality qualitative studies (Connell et al., 2001; Hinton et al., 2000) and one low
quality qualitative study (Williams et al., 2001). These provide more in-depth
material on barriers to recruitment among three minority ethnic groups in the USA.
African American recruitment
Focus groups in Connell et al. (2001) included 12 African-American
participants, who were asked additional questions about any specific concerns they
held about the research process. These questions elicited two primary themes
regarding barriers to participation. The first was strongly-held beliefs on helpseeking,
incorporating a preference for taking care of oneself without reference to outside
medical support, and fatalism about health outcomes. The second was scepticism
and suspicion about research and the procedures involved.
Chinese American recruitment
Hinton et al. (2000) report a detailed qualitative investigation of barriers to
recruiting Chinese American people with dementia and their carers to a study of
dementia caregiving. Themes identified included carers’ beliefs that a relative’s
dementia-related cognitive and behavioural changes were a normal and expected
part of aging, not a symptom warranting clinical or research scrutiny. Some carers
viewed research participation as potentially harmful because it might cause
excessive worry. The perceived stigma of Alzheimer’s also acted as a barrier. Data
may be seen as having increased validity from being gathered during an actual
study. Further strengths included a rigorous methodology, and inclusion of data from
those who had declined a study.
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Cuban American recruitment
Williams et al. (2001) drew on contemporaneous notes from researchers who
had attempted recruitment to an exercise intervention in residential homes, and had
found a high rate of refusal among Cuban-American family carers. The most
frequent barrier identified was the desire not to disturb the person’s comfort
(tranquilidad), this being seen as a right for people nearing the end of their lives.
Likewise, carers believed in the principals of solitude (soledad) – that the older
person should be left alone, and of futility (futilidad) – that there was no point in
intervening with their relative, and interfering with the natural course of things. They
also seemed to hold misperceptions of their relatives’ level of functional ability,
underestimating the amount they could still do. Strengths of the study include
culturally-informed exploration of factors involved in declining a study in a particular
population. Limitations include lack of clarity and detail in the description of study
design/methodology.
Summary
Three studies had a primary focus on cultural factors, identifying specific beliefs
and attitudes in different communities which acted as barriers to research
participation.
Difficulties in communication
This area was specifically covered in two papers. Guerriero-Austrom et al.
(2011) comment on how communication difficulties affected carer engagement with
the possibility of brain donation for their relative. These difficulties included
perceived lack of sensitivity around how the topic was introduced, the challenge of
developing a positive relationship between researcher and family, and the problem
of the researcher not understanding relevant family dynamics. Carers also
commented that they were not given the research information they needed, that they
felt their questions were not always answered, and that they lacked clarity on their
involvement in ongoing research. An interviewee in Connell et al. (2001) specifically
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commented that the lack of opportunity to communicate with researchers without
their family member present acted as a barrier to participation.
Summary
Though communication issues were mentioned as a barrier in only two studies,
it is notable that both related to the sensitive issue of brain donation.
Discussion
Main findings
The main motivators for dementia research participation identified or endorsed
by people with dementia or their carers were direct health benefit and altruism. Trust
in the sponsoring clinician or institution was also important. The main barriers were
concerns about risks/side effects of drugs and procedures, and the practical burden
of participation.
Less frequently identified barriers (in part due to fewer papers on these areas
being eligible for inclusion) were those specific to cultural groups (beliefs around
healthcare, the research process and dementia more generally), and those related
to brain donation (specifically, concerns about communication on this sensitive
topic).
Due to the wide variation in methodology, quality, and types of research
explored in the included studies, and the fact that not all studies explored both
motivators and barriers, or ranked these, it was not possible to provide overall
ranking of motivators or barriers, or claim with certainty that the findings are
generalisable across different study types.
Nevertheless, they are congruent with other summaries of factors affecting
dementia research recruitment and participation such as Knebl and Patki (2010),
Watson et al. (2014), and Cohen-Mansfield (2003). The findings from specific
minority ethnic populations are also consistent with existing work on this area (such
as Ballard, Gwyther, & Edmonds, 2010; Schnieders, Danner, McGuire, Reynolds, &
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Abner, 2013). Likewise, the difficulties around communicating over the issue of brain
donation have been previously described (Stevens, 1998).
Such papers sometimes draw on the same literature as the current review
(meaning some similarity would be expected). However as they also place their
findings in a wider context of clinical and research evidence, and draw on the
broader research participation literature, it may tentatively be argued that the
reliability and validity of the current findings are enhanced through this congruence.
Limitations of the review
Robustness of the search process
Within each paper included in the review, the focus of interest (opinions
volunteered or endorsed by people with dementia or their carers) was not always
the primary focus of the paper. Eligibility for inclusion was frequently not reliably
signalled by the paper title or abstract, and more detailed screening was required.
While the search strategy detailed above (p.14) attempted to allow for this by
using sufficiently inclusive search terms, additional resources would have allowed
for a more exhaustive search process, and may have identified further relevant
papers. When a broader search leads to an increase in the number of papers
identified for a review, this can increase the robustness of the subsequent narrative
synthesis (Ryan & Cochrane Consumers and Communication Review Group, 2013).
Potential for bias in quality assessment
Detailed scrutiny of quality both within and between the selected papers is
required to ensure that, as far as possible, the most methodologically sound papers
make the greatest contribution to the conclusions of the review (Pettigrew and
Gilbody, 2002).
In the current review, this scrutiny was based in the use of a quality appraisal
tool designed for a range of methodologies (see above, p.17, and Kmet et al., 2004).
This was employed to identify variations in quality between papers, and key quality
issues are highlighted in Table 1 (p.19, above) and paper summaries.
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It should be acknowledged that the quality ratings derived from this process
were assigned by a single rater (the review author). Kmet et al. (2004) acknowledge
that there is some subjectivity inherent in scoring using their assessment tools. This
is also the case for the assignment of overall quality ratings (as described above,
p.18).
To reduce the potential for bias, it would have been preferable to have two
people assessing quality, and to establish the level of inter-rater agreement both on
the assessment tool items and the derived overall quality ratings. This process could
then have been documented within the review as a support to readers in scrutinising
the findings.
Challenge of combining disparate methodologies
The possibility of confining the review to papers drawing on a single
methodology was considered. This would have supported quality comparison across
papers. However the scarcity of eligible literature was apparent at an early stage,
and to restrict inclusion to papers from a single methodology would have
exacerbated this further. The author considered that it was important to represent
the fullest possible range of views from people with dementia and carers, and thus
to include all eligible papers.
This did however compromise the comparability of papers in terms of quality,
given their fundamental methodological differences. It was hoped that the open
discussion of quality issues and ratings within the review would support readers in
making their own assessment of the validity of the search, selection and quality
appraisal process used, and of the relative value of each included paper in
answering the review questions.
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Limitations of the literature
As already acknowledged (‘Procedure’, p.17), the number of eligible papers
identified was limited, and quality, potential bias and focus of coverage varied
substantially.
Potential for bias within eligible studies
There was variation in whether papers addressed genuine (concluded,
ongoing, or yet to commence) or hypothetical studies. For concluded and ongoing
studies, only retrospective data were possible on factors influencing the decision
whether to participate. Recall bias may have been present (Hassan, 2005), with the
already-taken decision to participate, and subsequent investment in the process,
affecting the identification and weighting of factors underlying that decision.
Additionally, multiple factors may influence decision-making in hypothetical vs real
research situations (Kühberger, Schulte-Mecklenbeck, & Perner, 2002), making
unclear the extent to which we can rely on responses to a hypothetical scenarios
mirroring a real world situation.
Gathering data from both participants and those who declined studies occurred
only in Elad et al. (2000) and Karlawish et al. (2001). Had this been a more common
approach, it could have provided a more representative picture of how both
motivations and barriers influenced participation decisions across different research
situations.
Differences across research types
It was not possible in the current review reliably to establish differences
between themes emerging across different types of research (such as
pharmacological studies and psychological or behavioural interventions). More
detailed exploration of motivators and barriers which may be specific to each area
could be a fruitful research direction.
One such area is non-pharmacological studies. Cooper et al. (2014) noted the
lack of good quality data from such studies about factors influencing recruitment of
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people with dementia as participants. This remains the case, though at the time of
writing the current review, a protocol for a forthcoming systematic review and meta-
analysis which aimed to include data on factors associated with successful
recruitment of people with dementia to studies of psychological interventions had
recently been published (Farrand, Matthews, Dickens, Anderson, & Woodford,
2016).
Imbalance in international coverage
Given that the majority of included papers came from the US (and only 1 or 2
from each of the UK, Israel, Sweden and Australia), we cannot assume that the
tentative findings are generalisable across all these countries, or to countries not
represented in the eligible literature – further work would be needed to establish this.
Considerations for future recruitment
As highlighted in the introduction, recruitment remains a major difficulty in
dementia research. The findings of the current review tentatively support the idea
that direct health benefit (and/or improved care opportunities) for the person with
dementia is a leading motivator for clinical trial participation and, conversely,
concerns about the risks to the person’s health and wellbeing are a leading barrier.
It would not be ethical to encourage belief in the likelihood of direct medical benefit
for trial participants where this is not supported by evidence. Yet it could be
reasonable to convey benefits of participation such as additional health
checks/condition monitoring to potential recruits, as long as this information is not
overprivileged in comparison to possible risks.
The review findings also suggest that there are several broader motivations,
beyond the hope of direct benefit, which may incentivise participants and carers.
One way of helping people connect with such motivations could be to share service
user and carer testimony on these factors (such as altruism, social and emotional
benefit, and the maintenance of hope and agency). As Grill and Karlawish (2010)
suggest, if prospective participants can connect with a range of motivations for
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enrolment, they may be more likely both to consent to a study and to persist with it
through the research process.
Given that practical burden was also identified as a leading barrier to
participation, consideration should also be given at an early stage in the research
planning process as to how best to mitigate this – for example, through offering
home visits or arranging transport for participants and carers. Highlighting this when
recruiting may increase participation rates.
Finally, the findings suggest that communication may be a particular challenge
when attempted to recruit to brain donation studies. This implies that early
consideration of how to facilitate sensitive communication with potential donor
families may be beneficial in relationship-building and subsequent successful
recruitment in this area of research.
Recruitment from minority ethnic groups
The three papers which focused on barriers (or motivators) identified by specific
minority ethnic groups (African Americans, Cuban Americans and Chinese
Americans) include detailed data on barriers to research participation within each
group, and highlight practice which may best address these – including employing
researchers with relevant language and cultural knowledge, and developing
relationships with local communities to support trust and involvement in the research
process.
It is possible that the lack of culturally specific themes emerging in other papers
is an artefact of demographic imbalance in the samples recruited, rather than an
indication that cultural factors are not an important aspect of participation decisions
for people from minority ethnic communities. If this is the case, it would be
consistent with a known difficulty in dementia research about which future recruiters
should be vigilant. As demonstrated in Cooper, Tandy, Balamurali and Livingston’s
systematic review and meta-analysis (2010), people from minority ethnic
communities are less likely to access dementia research trials. They also tend to
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present later for diagnosis and to access less care and treatment, although they are
at greater risk of Alzheimer’s than the Caucasian population (Grill & Karlawish,
2010). There is a general need (highlighted by Cooper et al., 2010), for better
understanding of the factors underlying differential rates of access to dementia
services and research by specific cultural groups in different countries, and ongoing
work to support and bring together evidence and tailored recommendations to
support equity of access and outcome (such as those suggested in Connell et al.
(2010) and Dilworth-Anderson, Thaker, and Burke (2005).
In terms of future work to develop the current review’s focus on motivations and
barriers to research participation, the same issues apply: more research is needed
in countries beyond the USA in order to identify the factors identified as influencing
research participation by people with dementia and their carers from different
minority ethnic groups within those countries. This would allow recruitment
interventions to be targeted accordingly, and these under-represented groups more
effectively encouraged to access relevant studies.
Including the voice of people with dementia
Given the often essential role of a carer/study partner in facilitating the PWD’s
research involvement (Grill & Karlawish, 2010), it is perhaps unsurprising that many
papers in the review focused on carers’ views. These may also be seen as simpler
to access, especially where the PWD is more severely impaired. Yet this may lead
to an overgeneralised exclusion of people with dementia from research into
influences on participation.
However there is an ethical expectation that assent will be sought from the
PWD (Overton et al., 2013; Slaughter, Cole, Jennings, & Reimer, 2007) for
research, even when a proxy has responsibility for consent. Evidence suggests that
proxies do involve the PWD in their decision-making process (Sugarman et al.,
2001). It would be preferable in future research on this area to include both the PWD
and the carer/proxy wherever possible, pragmatically reflecting that both may
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influence the participation decision, and both have views of value. While this may
present challenges, existing studies suggest some potential avenues (Beuscher &
Grando, 2009; Cowdell, 2006, 2008), and such an approach would be consistent
with honouring the personhood of people with dementia.
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Part 2: Empirical paper
Mindfulness ability in people with mild to moderate dementia
62
Abstract
Background
People with dementia (PWD) experience high rates of depression, but it is
unclear whether they can benefit from mindfulness-based interventions (MBIs).
Aims
The study’s primary aim is to compare the performance of older people with
and without dementia on an experience-sampling measure of mindful attention. This
is a step towards exploring whether PWD can benefit from the mindfulness
component of MBIs. The secondary aim is to further develop the mindful attention
measure for use with PWD, by exploring convergent validity with a self-report
mindfulness measure.
Design
Thirty-four participants with dementia were recruited through memory services,
and tested face-to-face. A cross-sectional between groups design was used to
investigate the primary aim, with a cross-sectional correlational design for the
secondary aim. Comparison older adult data were taken from the DClinPsy thesis of
Noor Habib (Habib, 2016).
Measures
Measures of mindfulness (Meditation Breath Attention Task/MBAT, Cognitive
and Affective Mindfulness Scale (Revised)/CAMS-R), cognitive flexibility and
cognition (Trail Making Test/TMT, Addenbrooke’s Cognitive Examination III/ACE III),
and potential confounding variables (Hospital Anxiety and Depression Scale/HADS,
Test of Premorbid Functioning/TOPF) were administered.
Results
There were no significant findings for the main hypotheses, that people with
dementia would perform significantly more poorly than a comparison group of older
adults without dementia on the MBAT, and that performance on the MBAT would
positively correlate with measures of executive function and overall cognition. The
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groups differed significantly on a range of demographic characteristics and some
neuropsychological and mood measures.
Conclusions
Reasons for the null findings are unclear. Findings are considered in the
context of previous research and with reference to study limitations. Implications for
future research and practice are discussed.
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Introduction
Dementia and depression
Dementia is a progressive and chronic syndrome, with varying patterns of
impairment in cognitive and executive function, as well as emotional and
behavioural changes (World Health Organization, 2016). It is estimated that 46.8
million people worldwide are living with the condition (Prince et al., 2015), with an
estimated 850,000 in the UK alone (Prince et al., 2014). The economic cost of the
condition is high (estimated at £26.3 billion a year in the UK alone (Prince et al.,
2014)), as is the biopsychosocial impact on people living with dementia, and those
who care for them.
People with dementia tend to experience depression at far higher rates than the
non-dementia population (Winblad et al., 2004, cited in Enache, Winblad, &
Aarsland, 2011). It is estimated that 50% of people with dementia experience some
symptoms of depression, which increase functional impairment (Kales, Chen, Blow,
Welsh, & Mellow, 2005), decrease quality of life (Shin, Carter, Masterman,
Fairbanks, & Cummings, 2005), increase speed of cognitive decline (Rapp et al.,
2011), are associated with higher mortality rates (Suh & Yeon, 2005) and increase
carer stress (González-Salvador, Arango, Lyketsos, & Barba, 1999) and healthcare
costs (Kunik et al., 2003). Anxiety is also common and has a deleterious impact
(Orgeta, Qazi, Spector, & Orrell, 2015).
Mindfulness and depression
MBIs are already included within the evidence-based psychological
interventions for depression within the NHS. While cognitive behaviour therapy
(CBT) or interpersonal therapy (IPT) are the NICE-approved interventions for first
episodes of moderate to severe depression (in conjunction with medication if
appropriate), with CBT also recommended for people who have relapsed,
mindfulness-based cognitive therapy (MBCT) is recommended for those who have
experienced three or more depressive episodes (NICE, 2009).
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Mindfulness practice can be seen as helping avert or mitigate depressive
episodes through giving the practitioner a different relationship to difficult thoughts,
emotions and physical sensations. Repeated practice in noticing these, with
compassionate acceptance, means the person becomes more able to allow these
experiences to come and go without being drawn further into low mood, through
reducing engagement with unhelpful strategies such as depressive rumination (J. M.
G. Williams & Kuyken, 2012). While MBIs are not a standard intervention for people
with current depressive symptoms, there is a growing body of evidence for their use
in this context. The first meta-analysis of RCTs of MBIs with people currently
experiencing anxiety or depression found a positive impact for people with
symptoms of a current depressive disorder, concluding that MBIs might be
considered as an intervention for this population (Strauss, Cavanagh, Oliver, &
Pettman, 2014).
Treating depression in dementia
There is no good evidence for antidepressant use in dementia (Banerjee et al.,
2013), increasing the importance of exploring possible psychological interventions
for this population.
There is a small but increasing number of studies in this area, with some
promising initial findings, such as a pilot RCT (Spector et al., 2015) which found that
a tailored CBT intervention for anxiety in dementia was both feasible and effective.
In addition, Dr Joshua Stott’s ongoing PhD project is currently investigating
whether people with dementia are able to demonstrate capacities seen as key in the
use of cognitive behavioural therapy (CBT) for depression and anxiety. The current
study is a substudy of this project.
Mindfulness and dementia
Exploration of MBIs for people with dementia is also at an early stage. A small
pilot study (Leader, Litherland, Mason, Pilchick, Sansom, & Robertson, 2013)
suggested that mindfulness interventions (specifically mindfulness-based stress
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reduction, MBSR) could be taught to some people with dementia, especially in the
earlier stages, and that those who were able to learn and practice it found it
beneficial. The study nevertheless stated that the sample was too small to
generalise its conclusions and the researchers could not exclude the influence of
non-specific factors. More recent work (M. Y. Chan, 2015; Churcher-Clarke, 2015)
has found that people with dementia living in care homes experienced a significant
improvement in quality of life (as measured by the QoL-AD, (Logsdon, Gibbons,
McCurry, & Teri, 1999)) following a pilot group mindfulness intervention. Preliminary
work has also indicated the possible benefits of mindfulness-based stress reduction
for people with mild cognitive impairment (MCI) (Wells et al., 2013) which shares
some characteristics of dementia and confers an increased risk of developing
dementia.
Yet while the existing research does indicate that MBIs may have some utility in
dementia, the mechanisms remain unclear. The care-home based studies cited
above compared a group intervention to treatment as usual (continuing with normal
activities). As Chan (2015) notes, it is not possible confidently to attribute the
improvements seen to the specific therapeutic impact of mindfulness practice rather
than non-specific therapeutic effects of being in a regular group. The question
remains open as to whether people with dementia can engage with (and therefore
potentially benefit from) specific elements of mindfulness practice to the same level
as people without dementia, and thus whether further research and intervention
development in this area could be helpful.
There are also some prima facie reasons to believe that people with dementia
may find certain elements of mindfulness practice more difficult than people without
dementia.
Cognitive flexibility
The ability to attend (and to self-regulate attention) has been identified as one
of the two core components of mindfulness practices (the other being approaching
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present-moment experience with an orientation of curiosity, openness, and
acceptance (Bishop et al., 2006)). A study by Moore and Malinowski (2009)
demonstrated that these abilities (attentional performance and self-regulation of
attention, in the form of cognitive flexibility) are positively related to meditation
practice and levels of mindfulness. That study also suggested that mindfulness
ability and cognitive flexibility may be connected independently of meditation
practice, as the correlations between these two factors were also significant in a
non-meditating control group.
As deficit in executive function (encompassing cognitive flexibility) is a
diagnostic criterion for Alzheimer’s disease (World Health Organization, 2016), we
might therefore tentatively expect people with dementia to perform more poorly on a
task measuring mindful attention than people who do not have dementia (where
both groups are naïve to meditation). The current study focuses on the attentional
element in mindfulness practice.
Overall cognition
People with dementia also have impaired overall cognition (as measured by
screening tools such as the ACE III (Hsieh, Schubert, Hoon, Mioshi, & Hodges,
2013). Overall cognition has previously been shown to predict ability to engage in a
task of metacognition (cognitive restructuring) in older adults (Johnco, Wuthrich, &
Rapee, 2013), and the ability to metacognise (to think about one’s own thoughts) is
arguably fundamental to engaging in mindfulness practice (Teasdale, 1999).
Therefore impairment in this area may tentatively be expected to influence the ability
of people with dementia to perform well on a measure of mindful attention.
Methodological challenges in measuring mindfulness
Existing research has highlighted generic difficulties in researching mindfulness.
Bergomi, Tschacher, and Kupper (2012) provide an overview of some of the existing
validated measures, highlighting that all displayed flaws and specificities which
meant they were not generalisable across populations, or valid as a measure of a
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holistic concept of mindfulness. The majority of measures assessing mindfulness are
self-report in format, and in the same paper, the authors also enumerate the
difficulties of using self-report methods to assess mindfulness. Grossman (2008)
also details a number of systematic biases in using self-report measures in this
context, including the Hawthorne effect, the overconfidence effect, social desirability
responding, and cognitive dissonance.
Measuring mindfulness in dementia
The use of self-report measures may be additionally problematic for people with
a diagnosis of dementia, depending on their current severity. Smith et al. (2005)
highlight the ‘unique methodological challenges’ presented by the use of self-report
when attempting to assess a different variable in people with dementia, health-
related quality of life. These include disorders of memory, attention, expressive and
receptive language, judgment and behaviour. The authors do not completely
exclude the use of self-report in people with dementia, since competencies and
abilities will vary widely between individuals.
Therefore given the potential difficulties of self-report, particularly for people
with dementia, selecting a methodology which could reduce these possible
challenges in measuring mindfulness performance is an important consideration.
One possible alternative is the use of experience sampling methodology. This is a
means of tapping into a participant’s present-moment experience, and is therefore
less likely to be subject to self-report biases such as recall effects as well as having
increased ecological validity over a laboratory-based assessment (Scollon, Kim-
Prieto, & Diener, 2009). Experience sampling also has the benefit of reducing
demands on many aspects of cognition involved in delayed self-report, which, as
Smith et al. (2005) notes, may be additionally difficult for people with dementia
(including executive demands, sustained attention and prospective memory). One
such measure, developed specifically to measure mindful attention, is the Meditation
Breath Attention Task (MBAT) (Frewen, Evans, Maraj, Dozois, & Partridge, 2008).
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The MBAT also benefits from the ecological and face validity inherent in its close
approximation of a common element of meditation practice, mindfulness of
breathing.
Aims
The current study’s first aim is to establish whether, as is tentatively
expected, a group of higher-functioning people with dementia perform more poorly
than a comparison group of older people without dementia on the MBAT. This is a
key step towards establishing whether higher-functioning people with dementia
could engage with and benefit from the mindfulness component of MBIs for
depression, as opposed to their social interaction component.
As there is reason to expect that some core deficits of dementia (cognition and
executive function) might influence the performance of people with dementia,
discussion of the study findings will be aided by measuring these areas, as well as
the possible confounding factors of mood and premorbid IQ, and by exploring
correlations between these measures and the MBAT. Differences between the
group of people with dementia and the comparison group will also be explored.
The study’s second aim is to develop the evidence base for the MBAT in people
with dementia, to support future research in this population. This will be done by
exploring whether correlational analysis supports convergent validity of the MBAT
with a brief self-report measure of mindfulness, while acknowledging the challenges
of self-report.
Hypotheses
Hypotheses (tentative):
1) People with dementia will perform significantly more poorly than a comparison
group of older adults without dementia on the MBAT.
2) Performance on this measure will positively correlate with measures of
executive function and overall cognition. If these correlations are present it will be
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expected that performance on these measures predicts mindfulness performance
over and above mood and premorbid IQ.
Exploratory (convergent validity):
3) The study will explore whether there is an association between the performance
of people with dementia on the MBAT, and their score on a brief self-report measure
of mindfulness.
Method
Design
A cross-sectional between groups design was used to compare the
performance of the sample of people with dementia (PWD) and an older adult (OA)
comparison group on the MBAT. A cross-sectional correlational design was used to
explore the possibility of convergent validity between the mindful attention measure
and a self-report measure of mindfulness, and of associations between the mindful
attention measure and measures of core mindfulness-related cognitive and
executive deficit in dementia.
Setting
The dementia sample was collected across four memory services within two
foundation trusts in London, and their embedded dementia adviser services. To
reduce participant burden and facilitate attendance, most assessments were
conducted at participants’ homes.
Participants
Inclusion/exclusion criteria
Any patient on the memory service or dementia adviser caseloads, with a
dementia diagnosis, was potentially eligible for the study. The decision to contact
the patient to invite them to participate was based on further inclusion/exclusion
criteria, assessed by review of clinical notes and discussion with memory service
staff.
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A key screening criterion was a score of >70 on the ACE (or MMSE >24) in the
patient’s most recent diagnostic assessment. This threshold was selected as
representing a mild to moderate level of dementia such that prospective participants
were more likely to be able to give informed consent to participate, and be able to
functionally engage in the research tasks. Where this was uncertain, the clinical
judgement of the most closely involved memory service practitioner was followed.
Among participants who had completed the ACE some time previously, some were
found to have deteriorated in performance to below 70 on retesting. It was decided
not to exclude these participants from the study since they had demonstrated their
ability to give informed consent, and had been able to engage with the research
tasks during the appointment (these being pragmatic markers of being a higher-
functioning group). Had this not been the case they would have been excluded from
the study.
Exclusion criteria included the need for an interpreter, current significant
mood/anxiety disorders or psychotic symptoms, substance misuse problems or
premorbid learning disability, and sensory or physical disabilities or impairments
which would make engagement with the research measures difficult. Some patients
had previously stated they did not want to be contacted for research, or had
previously participated in a similar study, and were therefore excluded.
Participants were also excluded from the study if notes indicated previous
experience of mindfulness meditation, since the study was interested in naïve
performance on the mindfulness measure. Previous experience of cognitive
behavioural therapy (CBT) was also an exclusion factor, since the associated
project of the current study was interested in naïve performance on CBT-relevant
measures.
Ethics
Ethical approval for the study, and subsequent amendment (Appendices A and
B), was granted by the City Road and Hampstead National Research Ethics Service
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Committee. The study was also registered with research and development
departments local to the memory services involved.
Sample size
Although no previous study has used the full MBAT with comparable
populations, either as a within or between groups measure, medium to large effect
sizes have been found in a study with several parallels to the current research. In
Hebblethwaite, Jahoda, and Dagnan (2011), a different cognitively compromised
group (people with intellectual disability) was compared with controls with normal IQ,
on tasks which (like mindfulness) involved metacognitive ability, with N = 19 in each
group.
Due to the differences between Hebblethwaite et al. (2011) and the current
study, it was felt prudent to power the current study to detect a medium (rather than
large) effect, while aiming for the largest possible group sizes.
Power was calculated using G*Power (Kiel, 2007) for an independent groups t-
test for the primary hypothesis, that there would be a significant difference in
performance on the MBAT between PWD and the OA comparison group. (The
MBAT was treated as an interval variable, as had been the case in a study led by
the originator of the measure (Frewen, Lundberg, MacKinley, & Wrath, 2011)).
G*Power produced a requirement for a minimum N = 102 (51 participants in
each group) to detect a medium effect size (d = 0.5, with beta = 0.8 and alpha 0.05),
for a study involving equal size groups.
Measures
Neuropsychological, mood and mindfulness measures and demographic
questions were therefore administered along with measures specific to that study
(measuring CBT abilities), which are not reported here. The same measures were
used in the OA and dementia samples, with the exception of the CAMS-R which
was only used in the dementia sample.
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Demographic questions were always administered first, with the order of
presentation for mindfulness and neuropsychological measures counterbalanced.
The order of neuropsychological measures was always randomised to avoid order
effects. For the mindfulness measures, the self-report measure was always
presented before the experience-sampling measure. This was to reduce the
possibility of naïve participants’ response to the mindfulness exercise affecting their
subsequent self-report on the CAMS-R.
Mindfulness measures
Meditation Breath Attention Task (MBAT)
The MBAT, the development of which is described in Frewen et al. (2008),
was used to assess ability to mindfully attend to the breath. The MBAT is based on
the experience sampling method, and was selected for the current study to address
the need for a methodology more likely to avoid the difficulties of standard self-
report. The measure has strong ecological and face validity as ‘the ringing of bells
during silent meditation sittings as a form of reminding practitioners to return their
attention toward their breathing (if their attention has wandered) is a common
practice at mindfulness meditation retreats’ [and in both group and individual sitting
meditation practice] (Frewen et al., 2008).
In the task (see Appendix C), a ten minute practice period is followed by a 15
minute exercise in which participants are instructed to keep their attention on their
breath, noticing without judgement if their attention wanders, but then returning their
attention to the breath. A bell is rung at three minute intervals, with participants
instructed to raise one hand if their attention is on the breath, and the other hand if it
is elsewhere (the hand specified was counterbalanced across the sample to reduce
the potential impact of the dominant hand on responses).The number of times each
participant indicates that they were focused on the breath at the bell is recorded
(with a maximum possible score of five).
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Validity and reliability of the MBAT with adults has been demonstrated in
several studies. Frewen et al. (2008) demonstrated convergent validity in studies
with adult volunteers, finding MBAT scores to be significantly correlated with
relevant elements of the MAAS (Mindful Attention Awareness Scale), and three of
four subscales of the Kentucky Inventory of Mindfulness Skills (KIMS), both well
validated multidimensional measures of mindfulness (Baum et al., 2010). Further
evidence for convergent validity with the Five-Facet Mindfulness Questionnaire
(FFMQ) was supplied subsequently by Liu et al. (2013). Construct validity for the
measure has also been demonstrated (Lai, MacNeil, & Frewen, 2015; Frewen,
Lundberg, MacKinley, & Wrath, 2011), and a further study indicated good test-retest
reliability (Frewen, Unholzer, Logie-Hagan, & MacKinley, 2014).
Consideration was given to using a shorter version of the MBAT which involves
additional visual cues and verbal support from the researcher. This version was
used in the care home pilot study cited above (M. Y. Chan, 2015; Churcher-Clarke,
2015) to reduce task demands and increase acceptability and feasibility for people
with dementia. However the participants in that study were more impaired (the mean
MMSE score of 15.85 in the intervention group would have rendered them ineligible
for the current study, with its minimum MMSE of 24).
The author had also piloted the shorter measure in a memory service group of
higher-functioning people with dementia (who would have been eligible for the
current study), and found a ceiling effect in responses. It was therefore decided to
use the unadapted measure.
For the current study, a recorded version of the task was used to ensure
consistency of delivery for each participant (this was also used in the OA
comparison sample).
Cognitive and Affective Mindfulness Scale (Revised) (CAMS-R)
The CAMS-R (Feldman, Hayes, Kumar, Greeson, & Laurenceau, 2006,
Appendix D) is a brief (12-item) self-report measure sampling four domains of
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mindfulness – attention, present focus, awareness and acceptance/non-judgement.
It was used to assess convergent validity with the MBAT. Feldman et al. (2006)
previously demonstrated that the CAMS-R has acceptable internal consistency and
evidence of convergent and discriminant validity with concurrent measures of
mindfulness, distress, well-being, emotion-regulation, and problem-solving
approaches in three samples of university students, as well as finding that scores
were positively correlated with cognitive flexibility (p<0.1). As there is no existing
self-report measure of mindfulness validated for use with people with dementia, the
CAMS-R was selected as the briefest and least burdensome option available. While
some difficulties were reported with measure completion in the care home pilot
study mentioned above (J. Chan, personal communication, 5 December 2014), it
was anticipated that the current study’s higher-functioning population would
encounter fewer challenges in this regard. A focus group of higher-functioning
memory service patients had previously found the CAMS-R to be an acceptable
measure (J. Chan, personal communication, 11 March 2015).
Neuropsychological measures
Trail Making Test (TMT)
Cognitive flexibility was measured using the TMT (Appendix E), a two-part,
frequently used and acceptable measure for people with dementia, with excellent
inter-rater reliability (Bowie & Harvey, 2006), in which participants are asked to ‘join
the dots’ on a series of targets. In Trails A, this is a series of sequential numbers; in
part B, a series of alternating sequential numbers and letters. Trails B has support
as a measure of executive function (specifically, cognitive flexibility) (Kortte, Horner,
& Windham, 2002), and has been shown to significantly discriminate subjects with
and without dementia (Heun, Papassotiropoulos, & Jennssen, 1998).
Participants’ levels of cognitive flexibility is understood to be best represented
by using a score derived by combining Trails A and B scores (which reduces the
impact of other factors such as reduced motor and visual scanning speed on the
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Trails B set-switching task). It has been argued that the ratio score (Trails B score
divided by Trails A score) may be the preferred derived score as it correlates more
strongly with other measures of set-switching than the constituent scores
(Arbuthnott and Frank, 2000; Lamberty, 1994, cited in Hester, Kinsella, Ong, and
McGregor 2005). However more recent data (Sanchez-Cubillo et al., 2009) suggests
that the difference score (Trails B score minus Trails A score) could be a more
accurate reflection of set-switching ability. The difference score is used in the
current study.
Addenbrooke’s Cognitive Examination III (ACE III).
The ACE III (Appendix F) was used to assess overall cognition. It is a widely
used and acceptable measure with people with dementia and is frequently used as
a screening tool within memory services. It has been validated against its
predecessor the ACE-R and other standardised tests of neurological functioning in
early dementia (Hsieh et al., 2013), and has been shown to have high internal
reliability (Cronbach’s α = 0.88, (Velayudhan et al., 2014)). 
Measures of potentially confounding variables
Hospital Anxiety and Depression Scale (HADS)
The HADS (Appendix G) was used to identify whether clinically relevant levels
of anxiety and/or depression may be acting as a confounding factor in data analysis
of the main hypotheses. Anxiety and depression can influence cognition (Austin,
2001; Derakshan & Eysenck, 2009) which, as noted above (‘Overall cognition’,
p.67), may influence performance on a mindfulness task. In addition, depression
may affect motivation and effort to perform optimally during testing (Lezak,
Howieson, Bigler, & Tranel, 2012).
The HADS was developed to identify anxiety and depression among patients in
a hospital medical outpatient setting (Snaith & Zigmond, 1983). It has also been
used in community and outpatient settings (Dunbar, Ford, Hunt, & Der, 2000; Cacia 
et al., 2003), and is recommended for the identification of mood difficulties in primary
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care settings (NICE, 2009). It is an easy-to-administer, well accepted questionnaire
measure with acceptable internal consistency (Samaras et al., 2013), consisting of
14 self-report items equally contributing to two seven-item subscales assessing
depression and anxiety. Symptoms in the preceding week are rated by the
respondent on a four point Likert scale, with a maximum score of 21 on each
subscale. Higher scores correspond to higher disease severity (Johnston, Pollard, &
Hennessey, 2000; Herrero et al., 2003).  
The HADS has been used in research settings in patients with dementia
(Samaras et al., 2013) where it was found to be a feasible measure. It has
demonstrated good validity in assessing symptom severity and caseness of anxiety
and depression in medical, psychiatric and primary care patients and in the general
population (Bjelland, Dahl, Haug, & Neckelmann, 2002). As it does not assess
somatic symptoms of depression (which can be overlap with the physical impact of
illness/frailty), it reduces the chance of false positives for depression in screening
populations whose physical health is poorer.
Test of Premorbid Functioning (TOPF)
Estimated premorbid IQ was also considered to have the potential to act as a
confound in the data. There is evidence that for people with intellectual disability, IQ
level is related to poorer metacognitive ability (Hebblethwaite et al., 2011). It might
therefore also be suspected that in people with dementia, lower premorbid IQ level
would affect their ability to perform on a mindfulness task, beyond the potential
impact of dementia-related deficits. As this could reduce the confidence that might
be placed in any association found between membership of the dementia sample
and poorer performance on the MBAT, it was felt to be important to include a
separate measure of premorbid IQ.
Premorbid IQ estimates were derived from the score on the TOPF (Appendix H,
Wechsler, 2011), along with demographic information (gender, years of education).
The TOPF requires the reading and pronunciation of words with irregular grapheme-
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to-phoneme translation (which is relatively well preserved in early dementia
(Holdnack, Schoenberg, Lange, & Iverson, 2013), but not comprehension or
knowledge of word meaning. The TOPF was validated as part of the wider WAIS-
IV/WMS-IV UK validation process, which included a group study of people with
probable Alzheimer’s disease. Results were in line with the prediction that TOPF-
predicted IQ and memory would be higher than the obtained WMS and WAIS
scores, suggesting it has some utility as a measure of premorbid IQ in this
population.
Procedure
For the dementia sample, participants were recruited and assessed by three
researchers (the author and two research assistants), Recruitment was done via
three routes:
 In two services, a regularly updated database of people seen within the service
who had consented to research contact was reviewed at intervals. Patients meeting
key inclusion criteria were contacted directly for further screening. Staff caseloads
were also screened for patients who appeared to be eligible for the study but who
had not previously agreed to research contact. The researcher asked the staff
member to request consent to research contact from the patient.
 In one service, recruitment was done by screening of caseloads and of the
waiting list for the cognitive stimulation therapy group, which comprised a higher
functioning group of patients.
 In one service, recruitment was led by clinicians, who contacted the researcher
with details of eligible patients who had consented to contact.
Following this initial stage, patients were contacted by telephone. Information
about the study was provided (summarising key points of the participant information
sheet, Appendix I) and any questions answered. If the patient consented to
participate, an appointment was arranged.
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Participant information material for the study was reviewed at the start of the
appointment and written informed consent (Appendix J) obtained in line with the
agreed ethical procedures. Measures were then administered, with data recorded in
an online system, or on hard copy response forms and transferred to the electronic
system as soon as possible following the appointment. Following completion of the
measures, participants were asked for feedback on their experience of the research
process, including the mindful attention task. Finally, participants were thanked and
debriefed.
Data analysis
Data were analysed using SPSS version 22. Analyses were independent
groups t-tests or correlations, with non-parametric equivalents used where data did
not meet test assumptions.
OA comparison sample
The OA sample consisted of 55 healthy people aged 65 and above, recruited to
a parallel DClinPsy study which was also a substudy of Joshua Stott’s PhD study.
Participants were recruited via promotional activity in the University of the Third Age
and Age UK in London, as well as through snowball sampling. Eligibility criteria were
similar to the PWD sample, except that a diagnosis of dementia was an exclusion
criterion. In addition, data for participants who scored below the threshold for
identifying dementia on the ACE III on testing (which is 82) were excluded from
analysis. Participants who met eligibility criteria were primarily tested within an
academic setting.
The OA comparison sample were administered a similar battery of measures
(not including the CAMS-R) and used the same recording of the MBAT as the
current study. These data were used in the current study only to answer the primary
hypothesis about difference in MBAT performance between the groups. Other
analyses of the OA sample are reported in the DClinPsy thesis of Noor Habib
(Habib, 2016).
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Results
The flow of participants through the study is illustrated in Figure 1, below.
Figure 1: Flow of participants through the study
Demographic characteristics of the samples
Between groups analyses were carried out to assess any differences between
the groups on demographic characteristics (see Table 1, p.81). Statistically
significant differences (at the p<.001 level of significance) were found for age and
years of education - members of the dementia sample were older and had fewer
years of education than the OA sample. There were no statistically significant
differences found between groups for gender, ethnicity or marital status.
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Table 1: Demographic characteristics and results of between groups analyses for
PWD and OA participants
Group
PWD (N = 34) OA (N = 55)
Variable M
(SD)
M
(SD)
Test
statistic
Age 82.84
(6.58)
72.96
(6.30)
t = 7.06*
Years of
education
11.91a
(3.82)
16.07
(3.59)
t = 5.14*
n
(%)b
n
(%)b
Gender Male 17
(50)
21
(38)
 χ2 = 0.83
Female 17
(50)
34
(63)
Ethnicity White (English) 22
(65)
49
(89)
 χ2 = 10.25
White (Irish) 1
(3)
2
(4)
White (Other) 5
(15)
3
(6)
Mixed (White and
Black African)
1
(29)
0
(0)
Asian/Asian
British (Chinese)
1
(3)
0
(0)
Black/African/
Caribbean/Black
British
(Caribbean)
1
(3)
0
(0)
Black/African/
Caribbean/Black
British (Other)
2
(6)
0
(0)
Other ethnic
group (Other)
1
(3)
1
(2)
Marital
status
Single 5
(15)
7
(13)
 χ2 = 3.62
Married 12
(35)
29
(53)
Separated 0
(0)
1
(2)
Divorced 6
(18)
7
(13)
Widowed 11
(32)
11
(20)
*p <.001. aN = 33; bPercentages may not total 100 due to rounding.
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Neuropsychological, mood and self-reported mindfulness variables
Data for neuropsychological and mood variables, and for self-reported
mindfulness (CAMS-R) are shown in Table 2, below. All data for the MBAT are
presented in Table 3 (p.86).
Table 2: Data for neuropsychological, mood and self-reported mindfulness
variables by group
Group
PWD (N = 34) OA (N = 55)
Variable M
(SD)
Min-Max
M
(SD)
Min-Max
Test
statistic
ACE (/100) 74a
(10.84)
45-98
95.11
(4.42)
82-100
t = 10.67*
Estimated IQ 101.92a, b
(14.00)
75.90-126.40
118.70
(9.02)
93.30-132.60
t = 6.16*
TMT difference
score
166.58a
(76.36)
38-274
42.98
(35.94)
4-155
t = 8.80*
HADS (anxiety)
(/21)
4.94
(2.76)
1-12
4.55
(2.89)
0-12
t = 0.64
HADS (depression)
(/21)
5.35
(3.88)
0-14
2.47
(1.82)
0-7
t = 4.21*
CAMS-R (total)
(/48)
32.88
(4.74)
24-44
n/a d n/a d
*p=<0.001. a N = 33; b IQ estimates relate to premorbid IQ in PWD group; c N = 26;
d The CAMS-R was not administered to the OA group.
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Strategy for missing data
Variables other than the MBAT
While the majority of these 34 participants completed all measures, there were
some missing data. Before further analysis, Little’s MCAR test was performed (Little,
1988). When this test has a significant result, data cannot be assumed to be missing
completely at random (MCAR), which is a key assumption for using pairwise or
listwise exclusion in analysis rather than imputation to deal with missing data
(Graham, 2009). In this case, the p value was non-significant.
Graham (2009) advises the use of listwise rather than pairwise exclusion of
cases for missing data when data is MCAR, while acknowledging the potential loss
of power from excluding partial data from analysis. This was a consideration for the
current study, given that it was already somewhat underpowered. However Graham
comments that when the cases lost are not at a high percentage, both biases and
loss of power are likely to be inconsequential, and states a number of additional
reasons against pairwise deletion (Graham, p.554). Therefore it was decided to use
listwise deletion of cases in analyses for the current study.
Missing data for the MBAT
The amount of missing or ambiguous data was higher for the MBAT than the
other variables. While 26 of the 34 participants had completed the measure in full
according to instructions, six had given one or more ambiguous responses (e.g.
raising neither hand), and two did not complete the full exercise.
It was felt that listwise deletion, excluding 8/34 (24%) of cases from all analyses
involving the MBAT, would have too great an effect on the power of the study and
would further increase the risk of Type II error. Therefore for this variable only,
missing/ambiguous responses were imputed. While several methods for doing this
were considered (Gelman and Hill, 2006; Higgins and Green, 2011), the final
decision was to impute an assumed outcome. If the participant had failed to respond
clearly, or indicated they were not able to complete the task, the researcher saw this
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as indicating distraction or difficulty with the task which could plausibly be equated
with failure to attend to the breath. The missing or ambiguous responses were given
a score of ‘0’, as required in the MBAT for those who indicate they are not attending
to the breath at the bell.
Hypotheses
Hypothesis (tentative):
1) People with dementia will perform significantly more poorly than a
comparison group of older adults without dementia on the MBAT.
MBAT data were found not to meet the assumptions for parametric testing, as
the data distribution showed extreme negative skew and platykurtosis. Attempts to
transform the data were unsuccessful, therefore a non-parametric analysis was
used (Mann Whitney U test).
The results are shown in Table 3 (p.86). No statistically significant difference
was found between the groups (p = .38). The difference remained insignificant when
imputed data were excluded (p = .79).
Therefore the null hypothesis (that the groups came from a population with the
same median score) could not be rejected.
Considerations for further data analysis for the primary hypothesis
Consideration was then given to the possibility that the pre-existing group
differences found on demographic factors (such as age and years in education) may
have influenced this result by acting as covariates. Two main options were
considered for exploring this. These are outlined below, along with the reasons for
rejecting their use.
The first option considered was the application of ANCOVA as a way of
controlling for potential covariates. This was discounted since, as summarised in
Miller and Chapman (2001), the ANCOVA should not be used in naturally occurring
groups (such as those in the current study) since data could violate the assumption
of independence of observations within groups. It was felt that in the current study, it
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was possible that the significant between-group differences found on demographic
variables such as age and years of education were real group differences (i.e.
related at some level to the state of having dementia or not), rather than random
error (in which case attempting to control for the differences as covariates would be
appropriate).
Another approach considered was to attempt to mitigate for the pre-existing
group differences in age and years of education by selecting out cases from the OA
comparison group which most closely matched the PWD group on these
characteristics. However, this would have had the disadvantage of further reducing
the power of the study.
It was also considered that the stark group differences observed on these
demographic factors would be more likely to magnify any between-group difference
on the MBAT rather than mask it, further challenging the rationale for using either of
the above strategies. This view was based on findings such as those in Tombaugh
(2004) which assessed the impact of age and years in education on performance on
the TMT in 911 (non-cognitively impaired) adults aged 18-89. That study found that
performance covaried (worsened) with increased age and reduced years in
education. This would suggest that, were it possible to reduce the effect of age and
years in education on the outcome of the primary hypothesis in the current study,
the observed difference between groups would further reduce and no benefit would
be gained.
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Table 3: Results of Mann Whitney U tests with descriptive statistics for MBAT scores by group
Group
PWD (N = 34) OA (N = 55)
Variable Median Mode Min-Max Median Mode Min-Max df U z r
MBAT (with
imputed data)
3 5 0-5 4 4 0-5 87 1036.50* 0.88 0.09
MBAT (without
imputed data)a
4 5 0-5 4 4 0-5 79 689.50** -0.27 0.03
aN = 26; *p=.38; **p=.79.
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Hypothesis (tentative):
2) Performance on this measure will positively correlate with measures of
executive function and overall cognition. If these correlations are present it will
be expected that performance on these measures predicts mindfulness
performance over and above mood and premorbid IQ.
As planned, further exploratory analyses were considered for the PWD
sample, to assess whether there were associations between the MBAT score
and the two putative influencing mechanisms of cognition and cognitive
flexibility (plus the potential confounding variables of anxiety, depression and
estimated premorbid IQ).
Spearman’s rank order correlation was performed to assess the relationship
between the MBAT and the TMT difference score. Though the correlation was
statistically non-significant, the result displayed a trend towards significance (rs(31)=
.323, p=.067).
The same analysis was performed to assess the relationship between MBAT
and HADS (anxiety) scores. The resulting correlation was statistically non-significant
(rs(32)= .181, p=.306).
Correlational analyses for the MBAT and the ACE, HADS (depression) and
premorbid IQ were not performed, as assessment of bivariate scatterplots indicated
the distribution assumptions of the test were not met.
Exploratory (convergent validity):
3) The study will explore whether there is an association between the
performance of people with dementia on the MBAT, and their score on a
brief self-report holistic measure of mindfulness.
The bivariate scatterplot for the MBAT and CAMS-R was assessed as meeting
the distribution assumptions for Spearman’s rank-order correlation. There was no
statistically significant correlation between the measure of mindful attention to the
breath and self-reported mindfulness (rs(32)= .006, p=.971). This correlation
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coefficient is very close to zero (where a result of zero would suggest no relationship
between the ranks.)
Discussion
Summary of results
For the primary hypothesis, no statistically significant difference was found on
the measure of mindful attention between the group of PWD and the comparison
group of older adults. This was in spite of there being statistically significant
differences between the groups on measures of overall cognition, estimated
premorbid IQ, and executive ability, with PWD performing worse.
Further analysis aimed at exploring possible mechanisms influencing MBAT
performance in PWD found a tentative trend towards significance in the association
between cognitive flexibility (the TMT difference score) and score on the MBAT (p =
.067).
For the exploratory hypothesis, no statistically significant relationship was found
between the measure of mindful attention and the self-report measure of
mindfulness for PWD. Therefore the current study does not support convergent
validity for the MBAT with the CAMS-R in this sample.
These results were found in the context of the study being underpowered to
detect small to medium effects. This is discussed in more detail below, under
‘Limitations’ (p.93).
The context of previous research
For the first hypothesis, it is not possible to place the findings in the context of
directly parallel previous research, since there are no currently published studies
comparing groups on naïve performance on the MBAT. However the tentative
expectation that people with dementia would perform significantly worse than the
comparison group on the MBAT was based in known and well established
differences (also reflected in the findings of the current study) between people with
and without dementia, in areas which have a plausible theoretical link to the skills
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involved in engaging with the MBAT - cognition and cognitive flexibility. Possible
reasons underlying the non-significant finding are discussed below, under
‘Interpretation of findings’ (p.90).
For the exploratory hypothesis, convergent validity of the MBAT with a self-
reported measure of mindfulness (the CAMS-R) was not established in the current
study. However, as noted under ‘Measures’ (above, p.74), convergent validity of the
MBAT with several other well-validated measures of mindfulness has previously
been demonstrated in studies with adults. These have included findings of
significant correlations with the Mindful Attention Awareness Scale (MAAS), three of
four subscales of the Kentucky Inventory of Mindfulness Skills (KIMS), and the Five-
Facet Mindfulness Questionnaire (FFMQ) (Frewen et al., 2008; Lai et al., 2015).
Conversely, the CAMS-R has previously been found to have convergent validity
with other mindfulness measures, including a statistically significant association
(p<.001) with the MAAS (Feldman et al., 2006).
However a small number of previous studies using the MBAT report findings
which suggest convergent validity for the measure with other measures of
mindfulness is not always found. Frewen et al. (2011) did not find an association in
students between self-reported difficulty in attending to the breath and lower MBAT
score. The same study failed to replicate the Frewen et al. (2008) finding of a
moderate correlation between MBAS and trait mindfulness (the ‘Act with Awareness’
subscale of the KIMS).
Given the substantial variation in design, methodology and participant
characteristics across these studies, it is difficult to identify whether there are factors
common to the non-significant finding for convergent validity in the current study,
and in other studies with similarly non-significant findings for convergent validity.
Greater ease of comparison would have been possible had the current study
used a self-report mindfulness measure already established as having convergent
validity with the MBAT in an adult sample. However the CAMS-R was selected for
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both practical and ethical reasons, as a reliable and valid measure likely to be least
burdensome for participants to complete in the context of a substantial test battery.
Interpretation of findings
One possible explanation for the current null findings on the primary hypothesis,
given that the PWD group was a relatively high-functioning, community-dwelling
sample, is that there was in fact no significant difference between the PWD and OA
group’s underlying ability to pay sustained, mindful attention to the breath, as
measured by the MBAT. However, given the significant differences between the
groups on other measures of relevant skills in cognition and executive ability, it is
perhaps more likely that other factors influenced the outcome. As discussed below,
these may include a range of challenges to the validity and feasibility of the
measure, or that there was a significant but small difference between groups on the
MBAT which the study was underpowered to detect (Type II error).
Potential issues for validity and reliability of the MBAT
The current study was grounded in the existing evidence for the validity, reliability,
and feasibility of the MBAT as an experience-sampling measure of mindful attention
in adults (see above, p.73), and its merits in addressing some of the challenges to
validity found in standard self-report measures of mindfulness. However, the MBAT
still comprises elements which may lead to invalid, biased or incomplete responding
at different levels of the task. A number of these are scrutinised further below.
Construct validity of the task
Researchers subscribing to a methodological behaviourist perspective
(Pistrang, Barker, & Elliott, 2016) could argue that MBAT data is derived from
introspection by participants, who must still self-report their locus of attention. From
this perspective, even though the MBAT mitigates many problematic aspects of self-
report, it still could not have construct validity as a measure of mindful attention.
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Factors that may have affected valid responding
Social desirability bias
Even from a stance that valid self-report of an internal state is possible,
participant responses to the MBAT could still be affected by social desirability
factors (Paulhus, 1991). Participants could have intuited the desirable response
pattern for the MBAT from pre-existing social learning (at its simplest level, the
knowledge that paying attention is ‘better’ than being distracted). In such a
circumstance, it would be possible for a participant to accurately introspect their
attentional state but to misreport this (i.e., that they were ‘attending to the breath’
when their true state was of non-attention), in the hope of creating a more
favourable impression (Tourangeau et al, 2007, cited in Kaminska & Foulsham,
2013).
Cognitive dissonance
Cognitive dissonance (Festinger, 1962) could also have influenced response
choices. Participants with dementia frequently asked how well they had done on the
test battery, with some indicating anxiety about this. It is possible that a person with
dementia who wished to reassure themselves about their capacities might be biased
towards giving the ‘correct’ answer on the MBAT, to reduce their discomfort about
their cognitive difficulties, rather than carefully giving an accurate answer which
might not be congruent with a more positive self-image. It is also possible that
responses in the older adult comparison group could be affected through a similar
process, if the respondents had concerns about cognitive deterioration.
Anxiety under observation
It should be acknowledged that the MBAT differs from standard experience-
sampling measures, as, in the standard presentation of the measure, the researcher
is physically present with the participant. Thus participants are asked to undertake
an unfamiliar task, with their eyes closed, under close observation. As Frewen et al.
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(2008) note, being aware of others’ presence during such a task could increase
anxiety, and affect the ability to focus and report on the breath accurately.
Depression
Given the known impact of depression on motivation/effort (Lezak et al.,
2012) in testing, as well as on cognitive performance (Austin, 2001), low mood
should be considered as a further potential influence affecting valid responding and
task persistence. If this was the case, it may have differentially affected the PWD
sample, since HADS depression scores were significantly higher for this group
(reflecting higher rates in this population).
Inherent challenges of the task for the dementia sample
Though the task attempts to mitigate challenges of self-report, valid completion
still demands competence in a range of cognitive and executive areas which are
characteristically impaired in dementia. These are noted in Salmon and Bondi
(2009), with problems of delayed recall (leading to abnormally rapid forgetting)
foremost, as well as attention deficits which are most prominent in tasks requiring
the disengagement and shifting of attention, and memory tasks which rely on self-
control of attentional resources. Typical executive deficits include problems in cue-
directed behaviour and the concurrent manipulation and retention of information.
The MBAT asks participants to use all these capacities. They are required to
maintain attention to the breath for extended periods, and are then cued (by the bell)
to disengage from that focus of attention, and to set-shift into attending to and
processing the instructions being provided. They must simultaneously retain the
memory of where their attention was at the point the bell rang and subsequently use
this information in order to select the correct (accurate) response in terms of which
hand to raise. These requirements (themselves potentially problematic in dementia)
also necessitate a delay in responding once the bell has rung, which in itself could
affect a participant’s ability accurately to respond if they have impaired delayed
recall.
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Thus, although the MBAT may appear relatively simple to an observer, it
could be challenging for a person who has deficits of cognition and executive
function. The researcher hypothesised that this may explain some aspects of task
performance observed in the PWD group, and potentially have affected the validity
of their responses; a small number of participants responded impulsively (raising
their hand before the instructions were given), incongruently (raising the attending
hand but commenting later that they had not been attending), ambiguously (half
raising a hand then putting it down), or not at all.
It is also possible that the lack of awareness of impairment (‘anosognosia’)
typical of Alzheimer’s (Lorenzo & Tamietto, 2008) could combine with the deficits
detailed above to further problematise reliance on the validity of participant
responses.
Potential validity issues for the CAMS-R
The CAMS-R (a self-report measure) was administered only to the dementia
sample. The null finding for the exploratory hypothesis may have been influenced by
the additional difficulty which may be experienced in self-report in this population
(see above, p.68).
Limitations
Power issues and Type II error
Insufficient power may have affected the outcome of analyses in a number of
ways. Required group size had been calculated to achieve sufficient power in an
independent groups t-test to detect a medium effect. This had produced a
requirement of 51 participants in each group. This had already been met for the OA
comparison group, with 55 participants. Forty-six PWD were recruited and seen for
the study, getting close to the required level. However as only 34 were included in
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the analyses, for reasons covered above under ‘Missing data for the MBAT’ (see
above, p.83), the study was underpowered to detect medium effects.
Type II error is also more likely to be present in the results of non-parametric
tests (Field, 2013), which have lower power. As a non-parametric test (Mann
Whitney U) was required for analysis of the main hypothesis due to the abnormal
distribution of the data, this may also have contributed to the non-significant
findings.
Scores between the two groups on the primary hypothesis (difference in
performance on the MBAT) did differ in the tentatively expected direction (with PWD
having a lower median score), and this was associated with a small effect size (of
0.9). It is possible that the non-significant finding for this analysis represents Type II
error, with the effect being significant (though small), but with the study
underpowered to detect it.
Testing situation
Although the MBAT has ecological validity as a task of mindfulness practice, the
wider testing situation was less representative of a real world meditation setting.
Care is taken in meditation courses to aid focus and concentration by reducing or
removing sources of external distraction. Such a level of control was difficult to
achieve in participants’ homes, where the majority of testing for the PWD sample
took place. Sometimes family members/partners were present, occasionally
presenting a distraction to the participant. The researcher found some benefit from
including family members in the process of socialising the participant to the testing
situation (such as aiming for a quiet environment, with no prompting or intervention
on the tasks), but this was not always wholly successful..
Additionally, participants were asked to complete a substantial testing battery
immediately before the meditation task, which would not occur in the natural setting
of an MBCT for depression group. The extended testing period may have
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contributed to psychological fatigue, which has been shown to affect cognitive
performance (van der Linden, Frese, & Meijman, 2003).
Implications for future research
Given the pattern of findings and the underpowered nature of the study, future
research should aim to replicate the study with an adequate sample size, while
reducing as far as possible factors which may have affected the validity of the
testing process. This might include recruiting a more homogeneously high-
functioning dementia sample (e.g. by requiring a recent, higher cut-off on the ACE).
It could be useful for future researchers to incorporate a more formal measure
of task comprehension than was used in the current study, and for this feedback to
be sought immediately after the MBAT is administered (rather than at the end of a
longer battery of testing) to reduce the potential impact of dementia-related deficits
on participant responses. Having more reliable information as to the participants’
qualitative understanding of the measure could aid its future development for this
population. This might include the incorporation of more scaffolding elements into
the mindfulness task, such as shorter intervals and/or additional verbal and visual
cues, as used with the more impaired care home sample studied by Chan (2015)
and Churcher-Clarke (2015). This would still retain the face validity of the MBAT, as
it would parallel the introductory mindfulness of breathing exercises often used in
meditation courses.
Delivering the MBAT in the context of a more tightly focused battery of
assessments could also reduce the potential for participant fatigue which may
influence performance.
Acknowledging the problematic elements of any task involving self-report would
also suggest the need to develop alternate measures of the current construct of
interest (the attentional aspect of mindfulness as represented by attention to the
breath) through an objectively observable behaviour, in line with a methodologically
behaviourist stance. Another avenue would be to identify a different aspect of
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mindfulness practice which could be operationalised and measured as an
observable behaviour. A compromise approach might focus on retaining the
introspective aspect of the MBAT but further establishing (or disproving) its construct
validity. One element of this could be establishing convergent validity through
association with an observable behaviour representing the same construct (some
work has already been done in this area - see above, p.74). Frewen and colleagues
have also suggested the possibility of functional neuroimaging to investigate the
neural correlates of MBAT performance, based on the example of similar
investigations done for the related concept of mind-wandering (Andrews-Hanna et
al., 2010, cited in Frewen et al., 2011).
The current study was a cross-sectional study involving participants naïve to
meditation. A future study could usefully incorporate a longitudinal element, to move
beyond measuring baseline performance on the MBAT to exploring whether people
with dementia are able to increase their level of mindful attention through practice
(which would be a clinically relevant goal).
Clinical implications
The current study was aimed at developing the theoretical base for future
mindfulness interventions for depression, rather than piloting a specific clinical
intervention. However, it demonstrated that a majority of participants with dementia
were able to engage with the task, and a substantial minority reported enjoying it
and/or finding it relaxing.
We may therefore anticipate more generally that, since some higher-functioning
people with dementia are able to engage in the mindfulness process, mindfulness
may be seen as a potential mechanism of change for future clinical interventions
with this population.
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Part 3: Critical appraisal
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Introduction
This paper contains personal reflections on challenges that arose in my
research process. I comment on how I dealt with these, as well as making
suggestions that may aid future research. My focus is on issues and dilemmas
related to recruitment, consent and data collection.
Recruitment issues
When originally proposed, my research project had been designed as a cross-
sectional within-group study of people with dementia. That study was powered to
detect a medium effect size in a regression analysis, producing a required sample
size of 59. However it became apparent after several months of data collection that
this sample size was unachievable. This led to a change of design, to a between-
groups approach which meant that that the study was less underpowered. The
major impact that recruitment problems had on my research process led me to
reflect on some of the key factors I experienced as contributing to this difficulty.
Unreliable self-report during screening
As I note in the ‘Results’ section of the empirical paper, 46 people with
dementia were recruited for the study (which would have taken it close to achieving
the planned sample size). One of the reasons that six participants’ data had to be
discounted from analysis, affecting power, was ineligibility due to previous
experience of CBT or meditation being revealed at a late stage. This also meant that
a substantial amount of data collection time was spent with participants who were
ineligible for the study.
Retrograde amnesia is a recognised deficit of dementia (Salmon & Bondi,
2009), hence it is considered best practice when diagnosing the person not to rely
on self-report alone, but to get collateral input from someone who has known the
person well over a long period (Neugroschl, 2016). For future research, it is
important to remain mindful that memory difficulties can affect responses at all
stages of the recruitment and testing process, not only during formal testing.
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Therefore in future research, it could also be prudent to seek collateral information
during the screening process, if an accurate response is considered essential for the
study. However it must also be acknowledged that this will not always be possible,
as it relies on reliable collateral sources being available and accessible, which
clinical experience suggests is not always the case.
Inclusion criteria
With hindsight, it is arguable that the decision completely to exclude prospective
participants who disclosed past meditation experience could have been
disproportionate. Previous studies have attempted to account for past experience by
including a measure of the amount of previous meditation practice (Frewen,
Hargraves, DePierro, D’Andrea, & Flodrowski, 2016). This could be sensible in
future research.
Impact of health problems
The risk of dementia increases with age (with my sample having a mean age of
82), and with increasing age some level of physical change/deterioration is expected
(Ricklefs & Finch, 1995), though the nature and impact of this will vary greatly,
depending on a range of biopsychosocial factors. This can lead to a wide variation in
physical health and frailty in this population, with a proportion of older people living
with multiple comorbid conditions in addition to dementia (World Health
Organization, 2012). This can have a major impact on recruitment to research
(MacFarlane et al., 2015).
I saw at first hand the impact of this variability in the health of participants on my
ability to recruit sufficient numbers to power my study. Several potential participants
were excluded at an early stage either through screening their records, or by their
self-report during telephone screening, as their physical health status meant that
they would be unlikely to be able to engage with the research tasks, or might
experience harm. One example was a prospective participant with a diagnosis of
COPD, where research suggests that breath-focused meditation tasks could
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increase anxiety (R. R. Chan, Giardino, & Llarson, 2015). A further prospective
participant died before being seen.
The burden of health conditions extended beyond the potential impact of
symptoms on the testing process. I screened several participants who were involved
in multiple services for their physical health and associated support needs, with
regular appointments both at home and across different sites. It was common to
hear in such cases that people did not wish to engage in an additional appointment
to complete the research tasks, even if they supported the research aims in
principle. Research supports the idea of perceived inconvenience and burden as
deterrents to dementia research participation (Connell, Shaw, Holmes, & Foster,
2001; Dunn, Hoop, Misra, Fisher, & Roberts, 2011; Karlawish, Casarett, Klocinski, &
Sankar, 2001).
Some participants consented to and began the research appointment, yet we
agreed to end before the testing was complete due to their disclosure (or non-verbal
communication) of tiredness or discomfort. Furthermore, some participants were
seen across more than one session to allow for fatigue (which then had an effect on
the time available to see additional participants).
I attempted to reduce attrition of potential recruits by maintaining intermittent
contact (where consent for this was obtained) with those whose health was
fluctuating, as they anticipated possible future improvement (and thus ability to
engage in the study). This resulted in a small number of additional participants.
It seems inevitable that health-related difficulties will affect recruitment on a
study of people with dementia, especially given that the dementia is more likely to
be present in the context of existing health vulnerabilities and conditions including
diabetes, obesity, smoking, and hypertension (Baumgart et al., 2015).
Allowing as much time as possible for data collection, expecting attrition among
those who consent, and having access to a range of recruitment sources could all
be useful preparation for future similar studies.
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Over-research
All the memory services involved in the study were highly supportive of
research, in line with Memory Services National Accreditation Programme (MSNAP)
standards (Hodge, Hailey, & Orrell, 2016). This provided a supportive basis for
recruitment.
There were nevertheless challenges present. When a service was very
research-active (as were some of those in the current study) senior staff highlighted
the need to be wary of potentially ‘over-researching’ prospective participants
(http://www.ethicsguidebook.ac.uk/Over-researched-groups-86). Previous opinion
from another review of recruitment challenges supports the idea that lack of
competing studies can be a major influence on the ability to recruit, beyond the other
inherent challenges within this population (Grill & Karlawish, 2010) .
I and the other data collectors attempted to manage this by prioritising
approaches to those not involved in a current study. Where we did make tentative
contact with patients involved in other studies, it was not uncommon for them to
decline involvement while the current study was ongoing.
Personal qualms about recruitment
During the study I realised that I experienced qualms about approaching and
seeking participation from people with dementia. This was particularly the case
when the participant was someone I had assessed for dementia in my clinical work,
where I had concerns that their positive experience of our contact might mean they
felt obliged to help me, and where I felt, since their diagnosis was recent, they may
still be going through a process of adjustment. Furthermore, cognitive testing has
the potential to trigger emotional distress in vulnerable participants by reminding
them of cognitive difficulties to which they have not adjusted (J. M. Lai, Hawkins,
Gross, & Karlawish, 2008).
However I was also aware that being too tentative could hinder recruitment for a
study which aimed to benefit people with dementia (and thus their carers) in the
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future. I used research supervision to discuss these dilemmas, and to take a more
balanced view. This developed further during my contact with participants as I
gained more evidence on their actual responses to the research process.
I realised that it was helpful to remind myself that I was communicating
sensitively and respectfully with potential participants, and providing information in
an ethical way, in line with the guidance on ‘Informed consent to dementia research’
(Alzheimer Europe, n.d.). This always allowed people to decline participation, and it
was more likely that the sense of ‘pressuring’ was a fear of mine rather than being
perceived by the participant.
I also 1reflected that offering the opportunity for research participation was a
way of respecting the personhood of a person with dementia (Kitwood & Bredin,
1992) – by not pre-assuming that they lacked the ability to make their own decision,
but rather assessing this through our interaction. I also realised that for some
participants, research involvement was very much in line with their personal values.
Several told me about past careers in teaching and science which motivated them to
assist; I felt this suggested that participation was an opportunity to reconnect with a
valued part of their identity. It was also clear that some participants welcomed the
stimulation and social contact involved in the research visit. It was heartening to
have evidence that the process could be experienced as valuable in its own right for
these participants.
Consent issues
Avoiding misunderstandings during screening calls
Some prospective participants expressed confusion on hearing from me. They
had not retained the memory of their consent to research contact, and did not
understand why someone from the memory service was contacting them. Others
interpreted my summary of the study aims as suggesting that they themselves had
depression, and were keen to assure me ‘they were OK’ and didn’t need help in this
regard.
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Conversely, some participants, or their carers (if they had been delegated to
make practical arrangements) seemed to want to book the appointment time in
before I felt that they had received sufficient information to provide informed
consent. My perception was that this was a response reflecting behaviours
rehearsed in previous contact with clinical services. As I was calling from a service
they had previous contact with and support from, they may have assumed I was
offering a similar service. Were this the case, they would not have perceived a need
for more information from me in order for them to agree to an appointment.
A further number, hearing I was based in the memory service for the research,
were keen to participate as they felt it could help them with their memory problems.
Recruiting participants in such scenarios without correcting these assumptions
would have been unethical, since the result would have been uninformed refusal to
participate, or (more seriously) uninformed consent. Properly informed consent
through appropriately communicated information is a prerequisite for ethical
research (Alzheimer Europe, n.d.).
Such patterns of misunderstanding about my role and the possible benefit of the
research were evident early in my recruitment process. I countered them by
adapting the existing recruitment information further, and preparing a telephone
script which, while being succinct (important when sharing information with people
who are known to have some level of deficit in memory and possibly
communication), also ensured that the prospective recruit was aware from the
beginning of our conversation of the nature of my role and the purpose of my
contact with them. This gave me additional confidence that participant consent was
on an informed basis.
Ensuring direct consent from the participant
On a small number of occasions, a carer expressed that they were able to
consent to involvement in research on behalf of the person with dementia. While
having the support of the carers when arranging appointments was helpful, I was
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mindful of the ethical requirement for the current study that the person with dementia
themselves must understand and consent to involvement (and have capacity to do
so).
Where practical reasons meant it was not possible to get such consent by
phone at the time, this was dealt with by ensuring that the information and consent
process was thoroughly revisited with the person with dementia on the day of the
appointment. On one occasion where I felt the person’s own preference might be
conflicting with that of the carer, I used time alone with the person with dementia to
ensure they understood their right not to take part.
Reseeking consent
On some occasions, participants’ understandable difficulties in retaining
information meant that I arrived for a research appointment to find that the person
had forgotten our previous contact, and their previous agreement to participate.
To try and retain their involvement in an ethical way, I sought their permission to
remind them of the purpose of the study, and then resought consent without
assuming retention of any of our original discussion. It was clear that these
participants retained their capacity to consent when given appropriate information,
and wished to participate. Participants often welcomed the reminder calls we offered
prior to the appointment, and wherever possible we also sent a reminder letter as an
additional cue.
Challenges of data collection
Practicalities limiting volume of participants seen
Given the relatively limited time available for data collection, I had hoped to be
able to see up to three participants a day. However this proved unrealistic. The
length of time taken by each participant to complete the testing battery was hard to
predict, being influenced by their level of functioning, communication style, and need
for breaks. This made it impractical to book in testing appointments close together.
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Collecting data across four boroughs also meant allowing for considerable travel
time between participant visits.
Benefits and disadvantages of home visits
Being able to do home visits was essential to recruiting people with dementia to
the study. Both the clinical experience of the study team and existing research on
factors influencing dementia research participation (e.g. Karlawish, Cary, Rubright,
& Tenhave, 2008) suggest that the convenience of a home visit can compensate for
perceived disadvantages of research involvement, facilitating increased
participation.
My experience on this study supported this view. Several persons ambivalent
about participating were much keener to do so as soon as they understood that the
researcher could come to see them at home – it was important to inform them of this
at an early stage in the conversation. Pragmatically home visits can also benefit the
researcher. While seeing people in clinic could be more efficient than travelling
between home appointments, in a population with memory difficulties that may affect
attendance at pre-arranged appointments, a home visit is more likely to facilitate the
appointment successfully completing. As noted under ‘Reseeking consent’ (above,
p.113), I experienced contact with participants who had forgotten our arrangement
but were happy to continue when I arrived at their home and resought informed
consent. Had these individuals been offered a clinic appointment, it is possible that
they would not have attended and that a data collection opportunity would have
been lost.
While the ‘Limitations’ section of the empirical paper acknowledges some
difficulties that home visit settings may have imposed on the testing situation (such
as increased distraction), overall it seemed that the benefits of home visits for both
the participants and me outweighed the disadvantages.
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Involvement of carers/family members
A family member or carer was frequently present during the research
appointment. Research has demonstrated that carers (including formal study
partners) can play an essential role in supporting people with dementia’s
involvement in research (Black, Taylor, Rabins, & Karlawish, 2014), and my own
experience was that it was beneficial, both in helping the participant feel at ease,
and in facilitating practical elements of the appointment (such as reminding the
person about the appointment). However I also experienced some challenges
through the presence of the carer, in the form of distraction, or their attempts to help
the participant with the research tasks.
Once I had experienced the process several times, I started to develop ways of
working which explicitly incorporated the carer – welcoming their involvement and
socialising them to the testing process (for example, explaining why I asked them
not to help their family member answer questions). In effect I was pragmatically
seeking informed agreement from the carer as well as consent from the person with
dementia, recognising the role of the carer within the research process.
On a minority of occasions, the carer was present in the home but not
consistently in the same room, and happy to ‘let us get on with it’. However given
that testing extended over at least 1.5 hours, my presence represented a substantial
interruption to their daily routine. In such cases, interruptions into testing were the
norm. On one memorable occasion, a family member entered the room during the
meditation task, and expressed concern that the participant was apparently asleep
and exhausted by testing. I and the participant were able to reassure them that the
participant’s eyes were closed only as part of the mindfulness exercise.
In future similar studies, I would strongly recommend similarly involving the
carer (when they are present for testing) in an initial discussion of the logistics of the
appointment, in order to allay any concerns, and reduce the amount of distraction
and interruption that may occur.
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Clinical concerns in the research context
Although participants had been briefed that the study was not designed to
individually assess or aid their memory difficulties, it was understandable that the
testing process led some to ask questions and express concerns about their
performance, in the context of their known memory problems and dementia
diagnosis.
It was helpful to have considered the possibility of this occurring ahead of time
as part of the parent study’s protocols. I was able to respond to queries in a general
way, including giving basic and sensitive feedback on tests such as the ACE III, and
encouragement about accessing further support from sources such as the memory
service, GP, or local dementia adviser service. I learnt to be prepared with contact
details to facilitate this, since the person with dementia not infrequently (and
understandably) had not retained the memory of their contact at the memory
service, or the nature of support they could facilitate.
Being prepared in this way would be sensible for any research involving people
with dementia, where there is a possibility for some that participation may elicit
concerns which suggest clinical support could be helpful.
Conclusion
A range of factors related to the biopsychosocial nature of dementia as a
condition affected the current study in terms of recruitment, consent and data
collection. Anticipating such challenges and planning how they are best dealt with or
mitigated would be a sensible part of designing future research with this population.
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Appendix C: Script for Meditation Breath Attention Task (MBAT) (Frewen et al.,
2008)
What I’d like you to do first is just to sit at your chair quietly, and simply focus your mind on
your breathing. I know that you may have had to rush to get here, and may not be feeling
very much at ease. So please just take a few moments and relax your mind and body before
we get the study started. It’s important for you to feel relatively relaxed before we begin with
the actual meditation. So please just focus on your breathing and allow yourself to relax.
[pause 2-3 minutes]
Okay, if you are ready now and feeling relaxed enough to begin, we’ll get started…
What I’ll ask you to do first is to close your eyes. This might be a little awkward at first, but
don’t worry, this feeling should soon subside. [Note: Participants eyes remain closed now for
the duration of the exercise]
Now, and for the duration of this exercise, please begin to breathe both in and out through
your nose. Please do not breathe through your mouth. I’ll let you get used to this process
now for a few breaths. [pause 5-10 seconds]
Now please focus your attention on your breathing, and notice how you are breathing. [Not
expecting an actual answer:] Are you breathing slow or fast? Where do you notice your
breath? Is it in your chest or your abdomen? Just bring a gentle interest and inquisitive nature
into the process of your breathing.
[pause approx 5 seconds, then appropriately paced…]
Let’s observe our breathing process together now, from inhalation to exhalation. Notice
where your inhalation starts, at the nostrils. Now observe, if you can, your breath travel
down your nasal passage, and down into your lungs. Observe it there, and then observe the
moment when the inhalation ends and the exhalation begins. Observe your breath travel up
again now and out your nose.
[pause approx 5 seconds]
We will now do this again for 3 breaths, counting silently to ourselves before each breath.
Let’s practice…
[instructions are delivered slowly, as a means of pacing participants’ breathing…]
Say silently to yourself, “1”. And now, observe your breath as you breathe in through your
nostrils, observe your breath travel down into your lungs, observe the moment when the
inhalation ends and the exhalation begins, and observe your breath now travel up again and
out your nose.
[pause 2-3 seconds]
Now say silently to yourself, “2”. And now again, observe your breath as you breathe in
through your nostrils, observe your breath travel down into your lungs, observe the moment
when the inhalation ends and the exhalation begins, and observe your breath now travel up
again and out your nose.
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[pause 2-3 seconds]
Now say silently to yourself, “3”. And now once more, observe your breath as you breathe in
through your nostrils, observe your breath travel down into your lungs, observe the moment
when the inhalation ends and the exhalation begins, and observe your breath now travel up
again and out your nose.
[pause 2-3 seconds]
Now please continue to count your breaths, on your own, observing your breathing process
in this way for a total of ten breaths, beginning again at 1 and ending at 10. Begin by saying
silently to yourself, “1” and observe the process of your breathing through the inhalation to
the exhalation. Please try to keep your breath slow and relaxed.
[pause approx 45-60 seconds, saying at approx 20 seconds: “Please just continue breathing
in this way, keeping your eyes closed throughout, including when you have finished
observing your tenth breath…”]
Okay, I will assume now that you are done… Now you may have found this somewhat easy,
or you may have found it difficult to keep your attention focused on your breathing process.
That’s okay. It’s very normal to eventually become distracted by thoughts while trying to
attend to your breath; almost everyone gets distracted eventually and this is okay. It’s simply
a normal part of the nature of the human mind.
In fact the task that we will now be doing is one that is designed to measure how well you
are able to stay focused on your breathing, and not become too distracted by various
thoughts and feelings that you might have during meditation.
What you should do during this next meditation is just to sit silently, staying focused on the
process of your breathing, but this time WITHOUT counting your breaths. Just observe each
breath, from inhalation and exhalation, as we have been doing. This meditation will be for
[time in minutes, in our study this was 15 minutes].
If at any time during the meditation you find that your attention wanders to thinking about
something, daydreaming about the future or remembering something from the past, or you
experience a feeling or an emotion starts to come up, that’s okay, there’s no need to judge
yourself or get upset about this. Simply when you notice this happens, gently re-focus your
attention, as best you can, back to your breathing.
To measure how well you are able to keep your attention focused on your breathing, at
several points during the 15 minute meditation, you will hear a chiming tone like this [make
sound]. At these times, please raise your [right/left] hand if at that time your attention was
focused on your breathing, and your [left/right] hand if you were distracted and focusing on
thoughts, memories, emotions, or other things [counterbalance hand raising order]. Don’t
worry about remembering which is left and which is right though, I’ll repeat those
instructions each time the chime rings.
If you notice your attention wanders at times when the bell hasn’t just rung, you don’t have
to raise your hand. At these times, just gently re-focus your attention, as best you can, back
to your breathing. You only have to raise your hand to indicate whether your attention is on
your breathing at the times when the bell is rung, and not at other times.
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Okay, we will start the meditation now. Please begin again to focus your attention toward the
process of your breathing. Observe your breath as you breathe in through your nostrils,
observe your breath travel down into your lungs, observe the moment when the inhalation
ends and the exhalation begins, and observe your breath now travel up again and out your
nose. Continue to do this now, until you hear the first bell, keeping your eyes closed
throughout. Remember, you don’t need to count this time. Just focus on your breathing…
[Bell is chimed at 3 minute intervals. At these time points, after chiming the bell, say: “Now,
keeping your eyes closed, please raise your [right/left] hand if you were focusing on your
breathing, and your [left/right] hand if you were distracted or were focusing on thinking,
remembering something, or paying attention to feelings or emotions.”]
[Record responses for each participant as a repeated measure]
[Then say: “Okay, now return your focus to your breathing. Observe the process of your
breathing for each breath through the inhalation to the exhalation, trying to keep your
breathing slow and relaxed.”]
[Repeat for chimes 2-5. After fifth chime say: “Thank you. You have now completed the
mindfulness meditation exercise, and can open your eyes.
Meditation Breath Attention Score for each participant is simply the sum of the number of
times the participant indicated his or her attention was focused on his or her breathing during
the meditation exercise.
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Appendix E: Trail Making Test (TMT) Parts A and B
Redacted for test security and/or copyright
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Appendix F: Addenbrooke’s Cognitive Examination III (ACE III)
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Appendix G: Hospital Anxiety and Depression Scale
Redacted for test security and/or copyright
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Appendix H: Test of Premorbid Functioning (TOPF)
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